celecoxib has been researched along with Innate Inflammatory Response in 241 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " SPARCC inflammation scores of the SIJ and spine decreased in the three groups, and significant differences were found between the combined group and the celecoxib group [between-group difference: -6." | 9.51 | Etanercept/celecoxib on improving MRI inflammation of active ankylosing spondylitis: A multicenter, open-label, randomized clinical trial. ( Cao, S; Chen, Z; Gu, J; Jin, O; Kong, Q; Li, Q; Liao, Z; Lin, Z; Lv, Q; Pan, Y; Qi, J; Tu, L; Wang, X; Wei, Q; Ye, Z; Yu, Q; Zhao, M, 2022) |
| "Celecoxib has a significant inhibitory effect on postoperative aseptic inflammation." | 9.27 | Effect of Celecoxib on Surgical Site Inflammation after Total Knee Arthroplasty: A Randomized Controlled Study. ( Liu, Y; Lu, H; Ma, J; Sang, W; Xu, X; Zhu, L, 2018) |
| "Chemoprevention trials have shown that celecoxib reduces adenoma recurrence but can cause cardiovascular toxicity." | 9.17 | Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study. ( Arber, N; Coghill, AE; Duggan, D; Galazan, L; Gigic, B; Hummler, S; Kazanov, D; Kotzmann, J; Kraus, S; Makar, KW; Naumov, I; Poole, EM; Scherer, D; Toriola, AT; Ulrich, CM, 2013) |
| " The Adenoma Prevention with Celecoxib (APC) trial showed that the anti-inflammatory drug celecoxib prevents recurrence of colorectal adenoma but increases risk of cardiovascular events." | 9.15 | C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. ( Bertagnolli, MM; Chan, AT; Hawk, ET; Ridker, PM; Sima, CS; Zauber, AG, 2011) |
| "In this single-blind, controlled trial, consecutively hospitalized elderly patients (age > or = 70 years) with inflammation (C-reactive protein [CRP] levels > or =10 mg/L) due to acute infection were randomly assigned to receive 2 weeks of treatment with the COX-2-selective inhibitor celecoxib, acetaminophen, or no supplementary medication (control)." | 9.11 | The influence of celecoxib on muscle fatigue resistance and mobility in elderly patients with inflammation. ( Bautmans, I; Demanet, C; Lambert, M; Mets, T; Njemini, R, 2004) |
| " Celecoxib, an anti-inflammatory and analgesic agent indicated for the treatment of osteoarthritis and rheumatoid arthritis, is the first cyclooxygenase (COX) inhibitor with well-defined cyclooxygenase-2 (COX-2) specificity." | 8.80 | Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results. ( Tindall, E, 1999) |
| " Inspired by the role of cyclooxygenase-2 (COX-2) in inflammation in the tumor site, we proposed that normalization of the tumor microenvironment by celecoxib as a COX-2 inhibitor might improve the efficacy of Dendritic Cell (DC) therapy in a melanoma model." | 8.31 | Liposomal celecoxib combined with dendritic cell therapy enhances antitumor efficacy in melanoma. ( Arabi, L; Badiee, A; Jaafari, MR; Jahani, V; Yazdani, M, 2023) |
| "To analyze the changes in the levels of bone metabolism markers related to sacroiliac joint (SIJ) inflammation in patients with axial spondyloarthritis (axSpA) after treatment with imrecoxib and celecoxib and evaluate their relationship with clinical efficacy." | 8.31 | Imrecoxib and celecoxib affect sacroiliac joint inflammation in axSpA by regulating bone metabolism and angiogenesis. ( Chen, Y; Gao, G; Guo, Y; Jiang, D; Li, T; Mai, Z, 2023) |
| "Liver cirrhosis was induced by thioacetamide (TAA)." | 8.02 | Celecoxib ameliorates liver cirrhosis via reducing inflammation and oxidative stress along spleen-liver axis in rats. ( Gan, C; Gao, J; Huang, Z; Jia, X; Jiang, J; Liu, R; Ma, X; Su, W; Tai, Y; Tang, C; Tang, S; Wu, H; Ye, Y; Zhang, L; Zhao, C, 2021) |
| " Herein, we report the effect of both inflammation and NSAIDs (rofecoxib, celecoxib, and meloxicam) on the physiologically active cytochrome P450 metabolites of arachidonic acid (ArA) in the rat with adjuvant arthritis." | 7.88 | Drug-Disease Interaction: Effect of Inflammation and Nonsteroidal Anti-Inflammatory Drugs on Cytochrome P450 Metabolites of Arachidonic Acid. ( Aghazadeh-Habashi, A; Asghar, W; Jamali, F, 2018) |
| "The present study was done to investigate the ameliorative effect of silymarin (SMN) and celecoxib (CEL) on varicocele (VCL)-induced detrimental impact in testicular tissue." | 7.88 | Silymarin and celecoxib ameliorate experimental varicocele-induced pathogenesis: evidences for oxidative stress and inflammation inhibition. ( Mazhari, S; Razi, M; Sadrkhanlou, R, 2018) |
| "Finally, GTN and Celecoxib controlled inflammation in the prostate, and sensitized the senescent microenvironment to anti-inflammatory stimuli." | 7.85 | Goniothalamin and Celecoxib Effects During Aging: Targeting Pro-Inflammatory Mediators in Chemoprevention of Prostatic Disorders. ( Cagnon, VHA; Kido, LA; Montico, F; Pilli, RA; Vendramini-Costa, DB, 2017) |
| "We investigated the effects of metformin and celecoxib on obesity-induced adipose tissue inflammation, insulin resistance (IR), fatty liver, and high blood pressure in high-fat (HF) fed rats." | 7.83 | Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver. ( Hsieh, PS; Hung, YJ; Lu, CH, 2016) |
| " Compared with celecoxib controls, both oral and IA, ropivacaine IA treatment resulted in a significant reduction of pain upon successive PGPS reactivation, as demonstrated in two different pain models, gait analysis and incapacitance testing." | 7.81 | Intra-articular (IA) ropivacaine microparticle suspensions reduce pain, inflammation, cytokine, and substance p levels significantly more than oral or IA celecoxib in a rat model of arthritis. ( Balla, K; Bendele, A; Bogseth, R; Gass, J; Graham, S; Hutchcraft, A; Rabinow, B; Valaitis, P; Werling, J, 2015) |
| " Thus, the current study aimed at evaluating the effects of two testosterone boosting agents; chrysin, a natural flavone and celecoxib, a selective COX-2 inhibitor, in testicular impairment in rats with adjuvant arthritis, an experimental model of RA." | 7.80 | Chrysin alleviates testicular dysfunction in adjuvant arthritic rats via suppression of inflammation and apoptosis: comparison with celecoxib. ( Abdelsalam, RM; Arab, HH; Darwish, HA, 2014) |
| " Celecoxib (CXB), a selective COX-2 inhibitor, is able to control inflammation and pain, to improve the efficacy of radiotherapy, and to inhibit at high doses the growth of cancer cells." | 7.80 | New celecoxib multiparticulate systems to improve glioblastoma treatment. ( Barcia, E; Fernández-Carballido, A; García-García, L; Marcianes, P; Negro, S; Slowing, K; Vera, M, 2014) |
| " Our objective in this study was to determine the effects on HRV from exposure to nickel, an important chemical component of ambient PM that results in oxidative stress and inflammation." | 7.79 | Nickel-regulated heart rate variability: the roles of oxidative stress and inflammation. ( Chang, CC; Cheng, TJ; Chuang, HC; Chuang, KJ; Hsueh, TW; Hwang, JS; Yan, YH, 2013) |
| "Celecoxib selectively affects genes and pathways involved in inflammation and malignant transformation in tumor but not normal tissues, this may assist in the development of safer and more effective chemopreventive agents." | 7.77 | Gene expression following exposure to celecoxib in humans: pathways of inflammation and carcinogenesis are activated in tumors but not normal tissues. ( Arber, N; Domany, E; Kazanov, D; Kraus, S; Naumov, I; Sagiv, E; Shapira, S; Sheffer, M, 2011) |
| "Lornoxicam exhibits strong analgesic but weak antipyretic effects in rats with paw inflammation." | 7.75 | The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation. ( Arai, I; Futaki, N; Harada, M; Hashimoto, Y; Honma, Y; Hoshi, K; Nakaike, S; Sugimoto, M, 2009) |
| "The purpose of this study is to clarify involvement ratios between central and peripheral cyclooxygenase (COX)-2 in rat inflammatory pain models, by evaluating celecoxib and [6-chloro-2-(4-chlorobenzoyl)-1H-indol-3-yl]acetic acid (CIAA) on carrageenan-induced mechanical and thermal hyperalgesia." | 7.74 | Mathematical analysis of involvement ratio between central and peripheral COX-2 in rat pain models with two types of COX-2 inhibitors with different distribution, celecoxib and CIAA. ( Kita, Y; Murata, Y; Okumura, T; Sakakibara, A, 2008) |
| " In this study, the authors examined whether a selective COX-2 inhibitor (celecoxib) reduces cerebral inflammation and edema after intracerebral hemorrhage (ICH), and whether functional recovery is sustained with longer treatment." | 7.72 | Celecoxib induces functional recovery after intracerebral hemorrhage with reduction of brain edema and perihematomal cell death. ( Chu, K; Han, SY; Jeong, SW; Jung, KH; Kim, M; Lee, ST; Roh, JK, 2004) |
| "To investigate the action of celecoxib (a selective COX-2 inhibitor) in a rat model of colitis induced by trinitrobenzene sulfonic acid (TNBS)." | 7.72 | Effects and mechanism of the selective COX-2 inhibitor, celecoxib, on rat colitis induced by trinitrobenzene sulfonic acid. ( Dong, XY; Lu, YM; Zhang, L, 2004) |
| "This study evaluates the action of celecoxib and rofecoxib, two selective cyclooxygenase-2 (COX-2) inhibitors in two acute models of inflammation, carrageenan (Cg)-induced rat pleurisy, and paw oedema formation." | 7.71 | Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation. ( Calixto, JB; Pinheiro, RM, 2002) |
| "There was also no evidence that pre-treatment inflammation levels modified the effect of celecoxib augmentation versus placebo." | 7.01 | No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial. ( Baune, BT; Clark, SR; Fourrier, C; Hori, H; Louise, J; Mills, NT; Sampson, E; Schubert, KO, 2021) |
| "Standard dosing of the cyclooxygenase-2 inhibitor celecoxib slightly reduced perioperative cyclooxygenase activity during cancer surgery." | 6.84 | Impact of celecoxib on inflammation during cancer surgery: a randomized clinical trial. ( Hiller, JG; Ho, KM; Kuruvilla, N; Millen, R; Ramsay, R; Riedel, B; Sampurno, S, 2017) |
| " Low solubility and bioavailability issues related with celecoxib lead to the development and advancement in the discovery and research of some possible formulation administered either orally, topically or via transdermal route." | 6.66 | A journey of celecoxib from pain to cancer. ( Purohit, P; Saxena, P; Sharma, PK, 2020) |
| "Celecoxib was administered for 21 consecutive days, starting the day after hydrocephalus induction and continuing until the end of the experimental period." | 5.91 | Celecoxib attenuates neuroinflammation, reactive astrogliosis and promotes neuroprotection in young rats with experimental hydrocephalus. ( Covas da Silva, S; da Silva Beggiora Marques, P; da Silva Lopes, L; Dutra, LA; Dutra, M; Funo de Souza, SN; Machado, HR; Oliveira Amaral, I; Volpon Santos, M, 2023) |
| "Treatment of Celecoxib decreased DON-induced translocation of Protein Kinase C isozymes (α,ε,γ), demonstrating the role of PKC in DON-mediated biochemical and molecular alterations responsible for its dermal toxicity." | 5.56 | Celecoxib reduces Deoxynivalenol induced proliferation, inflammation and protein kinase C translocation via modulating downstream targets in mouse skin. ( Chaturvedi, S; Dewangan, J; Divakar, A; Kumar, S; Mandal, P; Mishra, S; Rath, SK; Srivastava, S; Tripathi, A; Wahajuddin, M, 2020) |
| " The relative bioavailability (BA) of the M3 and SD6 formulations was also significantly improved as oral bioavailability (167." | 5.56 | Therapeutic effects of celecoxib polymeric systems in rat models of inflammation and adjuvant-induced rheumatoid arthritis. ( Ahn, JB; Choi, JS; Heo, KS; Lee, DH; Myung, CS; Park, JS; Sim, S, 2020) |
| " SPARCC inflammation scores of the SIJ and spine decreased in the three groups, and significant differences were found between the combined group and the celecoxib group [between-group difference: -6." | 5.51 | Etanercept/celecoxib on improving MRI inflammation of active ankylosing spondylitis: A multicenter, open-label, randomized clinical trial. ( Cao, S; Chen, Z; Gu, J; Jin, O; Kong, Q; Li, Q; Liao, Z; Lin, Z; Lv, Q; Pan, Y; Qi, J; Tu, L; Wang, X; Wei, Q; Ye, Z; Yu, Q; Zhao, M, 2022) |
| "Ciprofloxacin and celecoxib were used in combination to regulate S." | 5.48 | Combination treatment of celecoxib and ciprofloxacin attenuates live S. aureus induced oxidative damage and inflammation in murine microglia via regulation of cytokine balance. ( Bishayi, B; Dey, R; Sultana, S, 2018) |
| "However, the role of COX-2 in epithelial ovarian cancer (EOC), and its mechanistic details, remain poorly understood." | 5.48 | COX-2 inhibition by celecoxib in epithelial ovarian cancer attenuates E-cadherin suppression through reduced Snail nuclear translocation. ( Li, CH; Li, XW; Wang, QY; Wang, YP, 2018) |
| "Kartogenin (KGN) is a small drug-like molecule that induces chondrogenesis in mesenchymal stem cells (MSCs)." | 5.48 | Kartogenin inhibits pain behavior, chondrocyte inflammation, and attenuates osteoarthritis progression in mice through induction of IL-10. ( Cho, KH; Cho, ML; Choi, J; Jung, K; Kim, SJ; Kwon, JY; Lee, CY; Lee, SH; Na, HS; Park, SH; Shin, DY, 2018) |
| "Rheumatoid arthritis is a chronic inflammatory disease characterized by overproduction of inflammatory mediators along with undermined oxidative defensive mechanisms." | 5.40 | Evening primrose oil and celecoxib inhibited pathological angiogenesis, inflammation, and oxidative stress in adjuvant-induced arthritis: novel role of angiopoietin-1. ( El-Azab, MF; El-Sayed, RM; Moustafa, YM, 2014) |
| "In the comparison of carcinogenesis, the percentage of normal tissue (i." | 5.40 | Combinational chemoprevention effect of celecoxib and an oral antiangiogenic LHD4 on colorectal carcinogenesis in mice. ( Alam, F; Byun, Y; Chung, SW; Jeon, OC; Kim, JY; Kim, SY; Park, J; Son, WC, 2014) |
| "Celecoxib is a selective cyclooxygenase-2 (COX2) inhibitor." | 5.39 | A trifluoromethyl analogue of celecoxib exerts beneficial effects in neuroinflammation. ( Alloza, I; Chiba, A; Di Penta, A; Miyake, S; Vandenbroeck, K; Villoslada, P; Wyssenbach, A; Yamamura, T, 2013) |
| "Celecoxib was administered at the rate of 3 mg/kg per day, loxoprofen at 3 mg/kg per day, and SC-58560 at 10 mg/kg per day." | 5.35 | Micro-CT imaging analysis for the effect of celecoxib, a cyclooxygenase-2 inhibitor, on inflammatory bone destruction in adjuvant arthritis rats. ( Kimoto, A; Miyata, K; Noguchi, M; Sasamata, M, 2008) |
| "Celecoxib and aspirin were ineffective at preventing lung tumorigenesis in a two-stage carcinogenesis protocol in which 3-methylcholanthrene administration is followed by chronic BHT." | 5.31 | Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice. ( Barrett, BS; Bauer, AK; Dwyer-Nield, LD; Kisley, LR; Malkinson, AM; Thompson, DC, 2002) |
| "Celecoxib has a significant inhibitory effect on postoperative aseptic inflammation." | 5.27 | Effect of Celecoxib on Surgical Site Inflammation after Total Knee Arthroplasty: A Randomized Controlled Study. ( Liu, Y; Lu, H; Ma, J; Sang, W; Xu, X; Zhu, L, 2018) |
| "With a lower efficacy than Sou-Medrol in decreasing postoperative inflammation, celecoxib produces a better effect in inhibiting COX-2 expression, but it does not lower postoperative recurrence rate of rectal cancer." | 5.20 | [Perioperative immunomodulatory therapy does not decrease postoperative recurrence rate of rectal cancer]. ( Gan, ZM; Li, L; Liu, D; Lv, DH; Wang, XD, 2015) |
| "Chemoprevention trials have shown that celecoxib reduces adenoma recurrence but can cause cardiovascular toxicity." | 5.17 | Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study. ( Arber, N; Coghill, AE; Duggan, D; Galazan, L; Gigic, B; Hummler, S; Kazanov, D; Kotzmann, J; Kraus, S; Makar, KW; Naumov, I; Poole, EM; Scherer, D; Toriola, AT; Ulrich, CM, 2013) |
| " The Adenoma Prevention with Celecoxib (APC) trial showed that the anti-inflammatory drug celecoxib prevents recurrence of colorectal adenoma but increases risk of cardiovascular events." | 5.15 | C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. ( Bertagnolli, MM; Chan, AT; Hawk, ET; Ridker, PM; Sima, CS; Zauber, AG, 2011) |
| "In this single-blind, controlled trial, consecutively hospitalized elderly patients (age > or = 70 years) with inflammation (C-reactive protein [CRP] levels > or =10 mg/L) due to acute infection were randomly assigned to receive 2 weeks of treatment with the COX-2-selective inhibitor celecoxib, acetaminophen, or no supplementary medication (control)." | 5.11 | The influence of celecoxib on muscle fatigue resistance and mobility in elderly patients with inflammation. ( Bautmans, I; Demanet, C; Lambert, M; Mets, T; Njemini, R, 2004) |
| "Analysis of randomized controlled trials from the Pfizer clinical trial repository (final study reports completed by 31 July 2011) in which celecoxib was compared with placebo or non-selective non-steroidal anti-inflammatory drugs (nsNSAIDs) for treatment of pain or inflammation in adults." | 4.89 | Safety of celecoxib compared with placebo and non-selective NSAIDs: cumulative meta-analysis of 89 randomized controlled trials. ( Berger, MF; Essex, MN; Park, PW; Upadhyay, S; Zhang, RY, 2013) |
| " Celecoxib, an anti-inflammatory and analgesic agent indicated for the treatment of osteoarthritis and rheumatoid arthritis, is the first cyclooxygenase (COX) inhibitor with well-defined cyclooxygenase-2 (COX-2) specificity." | 4.80 | Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results. ( Tindall, E, 1999) |
| " Inspired by the role of cyclooxygenase-2 (COX-2) in inflammation in the tumor site, we proposed that normalization of the tumor microenvironment by celecoxib as a COX-2 inhibitor might improve the efficacy of Dendritic Cell (DC) therapy in a melanoma model." | 4.31 | Liposomal celecoxib combined with dendritic cell therapy enhances antitumor efficacy in melanoma. ( Arabi, L; Badiee, A; Jaafari, MR; Jahani, V; Yazdani, M, 2023) |
| "To analyze the changes in the levels of bone metabolism markers related to sacroiliac joint (SIJ) inflammation in patients with axial spondyloarthritis (axSpA) after treatment with imrecoxib and celecoxib and evaluate their relationship with clinical efficacy." | 4.31 | Imrecoxib and celecoxib affect sacroiliac joint inflammation in axSpA by regulating bone metabolism and angiogenesis. ( Chen, Y; Gao, G; Guo, Y; Jiang, D; Li, T; Mai, Z, 2023) |
| " One novel lncRNA relevant to inflammation and arachidonic acid (AA) metabolism is the p50-associated COX-2 extragenic RNA (PACER)." | 4.12 | PACER lncRNA regulates COX-2 expression in lung cancer cells. ( Desind, SZ; Iacona, JR; Lutz, CS; Mitrofanova, A; Yu, CY, 2022) |
| "In summary, we have demonstrated a new use for the old drug Celecoxib that treats intervertebral disc degeneration by enhancing autophagy in nucleus pulposus cells and opening a door for treating other degenerative diseases." | 4.12 | Celecoxib activates autophagy by inhibiting the mTOR signaling pathway and prevents apoptosis in nucleus pulposus cells. ( Chen, W; Jiang, L; Lin, H; Lu, S; Wang, H; Wang, Z; Yasen, M; Zhuang, C, 2022) |
| "Liver cirrhosis was induced by thioacetamide (TAA)." | 4.02 | Celecoxib ameliorates liver cirrhosis via reducing inflammation and oxidative stress along spleen-liver axis in rats. ( Gan, C; Gao, J; Huang, Z; Jia, X; Jiang, J; Liu, R; Ma, X; Su, W; Tai, Y; Tang, C; Tang, S; Wu, H; Ye, Y; Zhang, L; Zhao, C, 2021) |
| " Therefore, this study examined the effect of KML29 alone as well as in combination with low-dose celecoxib (CXB) on joint pain and inflammation in the monoiodoacetate (MIA) model of osteoarthritis (OA) pain." | 3.96 | Combatting joint pain and inflammation by dual inhibition of monoacylglycerol lipase and cyclooxygenase-2 in a rat model of osteoarthritis. ( McDougall, JJ; Philpott, HT, 2020) |
| "In this study, the role of inflammation in traumatic heterotopic ossification around temporomandibular joint (THO-TMJ), as well as the preventive and treatment effect of celecoxib in THO-TMJ both in vivo and in vitro were explored." | 3.96 | The effect of celecoxib in traumatic heterotopic ossification around temporomandibular joint in mice. ( Chen, L; Chen, Q; Dai, J; Fang, B; Ouyang, N; Shen, G; Zhao, Y, 2020) |
| " Herein, we report the effect of both inflammation and NSAIDs (rofecoxib, celecoxib, and meloxicam) on the physiologically active cytochrome P450 metabolites of arachidonic acid (ArA) in the rat with adjuvant arthritis." | 3.88 | Drug-Disease Interaction: Effect of Inflammation and Nonsteroidal Anti-Inflammatory Drugs on Cytochrome P450 Metabolites of Arachidonic Acid. ( Aghazadeh-Habashi, A; Asghar, W; Jamali, F, 2018) |
| " In this study, we compared the release profile of prostanoids, which are involved in inflammation, of HFP from OA patients vs patients with a focal cartilage defect (CD) without evidence for OA on MRI and investigated the prostanoid modulatory anti-inflammatory action of celecoxib on HFP." | 3.88 | Celecoxib-mediated reduction of prostanoid release in Hoffa's fat pad from donors with cartilage pathology results in an attenuated inflammatory phenotype. ( Bastiaansen-Jenniskens, YM; Caron, MMJ; Emans, PJ; Timur, UT; van Osch, GJVM; van Rhijn, LW; Welting, TJM, 2018) |
| "The present study was done to investigate the ameliorative effect of silymarin (SMN) and celecoxib (CEL) on varicocele (VCL)-induced detrimental impact in testicular tissue." | 3.88 | Silymarin and celecoxib ameliorate experimental varicocele-induced pathogenesis: evidences for oxidative stress and inflammation inhibition. ( Mazhari, S; Razi, M; Sadrkhanlou, R, 2018) |
| "As an effective COX-2 inhibitor, celecoxib is widely used in anti-inflammation therapy." | 3.85 | Enhanced Anti-Inflammatory Efficacy Through Targeting to Macrophages: Synthesis and In Vitro Evaluation of Folate-Glycine-Celecoxib. ( Li, Y; Xiao, Y; Yin, Z, 2017) |
| " At this time, celecoxib is the only available COX-2-specific inhibitor for treatment of pain and inflammation." | 3.85 | COX-2-dependent and independent effects of COX-2 inhibitors and NSAIDs on proatherogenic changes in human monocytes/macrophages. ( Carsons, SE; De Leon, J; Gomolin, IH; Kasselman, LJ; Littlefield, MJ; Reiss, AB; Voloshyna, I, 2017) |
| "Celecoxib has protective effects on sepsis due to its preservative effects on mesenteric perfusion, aortic function and its anti-inflammatory and antioxidative effects." | 3.85 | Celecoxib administration reduced mortality, mesenteric hypoperfusion, aortic dysfunction and multiple organ injury in septic rats. ( Bariskaner, H; Goktas, MT; Iskit, AB; Kilinc, I; Ozer, EK; Ugurluoglu, C, 2017) |
| "Finally, GTN and Celecoxib controlled inflammation in the prostate, and sensitized the senescent microenvironment to anti-inflammatory stimuli." | 3.85 | Goniothalamin and Celecoxib Effects During Aging: Targeting Pro-Inflammatory Mediators in Chemoprevention of Prostatic Disorders. ( Cagnon, VHA; Kido, LA; Montico, F; Pilli, RA; Vendramini-Costa, DB, 2017) |
| "We investigated the effects of metformin and celecoxib on obesity-induced adipose tissue inflammation, insulin resistance (IR), fatty liver, and high blood pressure in high-fat (HF) fed rats." | 3.83 | Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver. ( Hsieh, PS; Hung, YJ; Lu, CH, 2016) |
| "9% bromfenac (Xibrom™) or a celecoxib-impregnated intraocular lens (celecoxib-IOL) compared with 1% prednisolone acetate (PA) in controlling postoperative inflammation and posterior capsule opacification (PCO)." | 3.81 | Efficacy of COX-2 inhibitors in controlling inflammation and capsular opacification after phacoemulsification cataract removal. ( Brookshire, HL; English, RV; Gift, BW; Gilger, BC; Nadelstein, B; Weigt, AK, 2015) |
| " Compared with celecoxib controls, both oral and IA, ropivacaine IA treatment resulted in a significant reduction of pain upon successive PGPS reactivation, as demonstrated in two different pain models, gait analysis and incapacitance testing." | 3.81 | Intra-articular (IA) ropivacaine microparticle suspensions reduce pain, inflammation, cytokine, and substance p levels significantly more than oral or IA celecoxib in a rat model of arthritis. ( Balla, K; Bendele, A; Bogseth, R; Gass, J; Graham, S; Hutchcraft, A; Rabinow, B; Valaitis, P; Werling, J, 2015) |
| " Here, we present a theranostic nanoemulsion platform for simultaneous delivery of an anti-inflammatory drug (celecoxib) to macrophages and monitoring of macrophage migration patterns by optical imaging, as measurement of changes in inflammation." | 3.81 | Theranostic nanoemulsions for macrophage COX-2 inhibition in a murine inflammation model. ( Anderson, CJ; Beaino, W; Janjic, JM; Patel, SK, 2015) |
| " Colonic delivery of celecoxib elicits anticolitic effects in a trinitrobenzene sulfonic acid-induced rat colitis model." | 3.81 | Evaluation of glycine-bearing celecoxib derivatives as a colon-specific mutual prodrug acting on nuclear factor-κB, an anti-inflammatory target. ( Jeong, S; Jung, Y; Kim, MS; Kim, W; Lee, S; Lee, Y; Moon, HR; Nam, J; Yoo, JW, 2015) |
| " While all the compounds (20mg/kg) showed significant anti-inflammatory activity after 3h of inflammation induction (69-89%) as compared to celecoxib (80%), 1-(4-methanesulfonylphenyl)-5-(4-methylaminomethylphenyl)-3-trifluoromethyl-1H-pyrazole (12 a) was found to be the most effective one (89%)." | 3.80 | Synthesis of new 1-(4-methane(amino)sulfonylphenyl)-5-(4-substituted-aminomethylphenyl)-3-trifluoromethyl-1H-pyrazoles: a search for novel nitric oxide donor anti-inflammatory agents. ( Abdellatif, KR; Knaus, EE; Moawad, A, 2014) |
| " These results suggest that ceftriaxone, particularly in combinations with ibuprofen, celecoxib, paracetamol, or levetiracetam, may provide useful approach to the clinical treatment of inflammation-related pain." | 3.80 | Antihyperalgesic/antinociceptive effects of ceftriaxone and its synergistic interactions with different analgesics in inflammatory pain in rodents. ( Boškovic, BD; Kovacevic, JM; Micov, AM; Stepanovic-Petrovic, RM; Tomic, MA, 2014) |
| "Several studies have shown the anti-neoplastic effects of non-steroidal anti-inflammatory drugs (NSAIDs) on 1,2-dimethylhydrazine (DMH)-induced colon carcinogenesis, but how these drugs act in case of inflammation-augmented tumorigenesis is still not clear." | 3.80 | Activation of NF-κB: bridging the gap between inflammation and cancer in colitis-mediated colon carcinogenesis. ( Nehru, B; Sanyal, SN; Setia, S, 2014) |
| " Thus, the current study aimed at evaluating the effects of two testosterone boosting agents; chrysin, a natural flavone and celecoxib, a selective COX-2 inhibitor, in testicular impairment in rats with adjuvant arthritis, an experimental model of RA." | 3.80 | Chrysin alleviates testicular dysfunction in adjuvant arthritic rats via suppression of inflammation and apoptosis: comparison with celecoxib. ( Abdelsalam, RM; Arab, HH; Darwish, HA, 2014) |
| " Celecoxib (CXB), a selective COX-2 inhibitor, is able to control inflammation and pain, to improve the efficacy of radiotherapy, and to inhibit at high doses the growth of cancer cells." | 3.80 | New celecoxib multiparticulate systems to improve glioblastoma treatment. ( Barcia, E; Fernández-Carballido, A; García-García, L; Marcianes, P; Negro, S; Slowing, K; Vera, M, 2014) |
| " The objective of the current study was to examine whether celecoxib, a selective COX-2 inhibitor, could ameliorate lipopolysaccharide (LPS)-induced brain inflammation, dopaminergic neuronal dysfunction and sensorimotor behavioral impairments." | 3.79 | Celecoxib reduces brain dopaminergic neuronaldysfunction, and improves sensorimotor behavioral performance in neonatal rats exposed to systemic lipopolysaccharide. ( Bhatt, AJ; Cai, Z; Fan, LW; Kaizaki, A; Numazawa, S; Pang, Y; Tanaka, S; Tien, LT, 2013) |
| " This study characterized the manner in which levetiracetam interacts with analgesics (ibuprofen, celecoxib, and paracetamol) and caffeine to suppress hyperalgesia in a model of localized inflammation." | 3.79 | Levetiracetam interacts synergistically with nonsteroidal analgesics and caffeine to produce antihyperalgesia in rats. ( Micov, AM; Stepanović-Petrović, RM; Tomić, MA, 2013) |
| " Our objective in this study was to determine the effects on HRV from exposure to nickel, an important chemical component of ambient PM that results in oxidative stress and inflammation." | 3.79 | Nickel-regulated heart rate variability: the roles of oxidative stress and inflammation. ( Chang, CC; Cheng, TJ; Chuang, HC; Chuang, KJ; Hsueh, TW; Hwang, JS; Yan, YH, 2013) |
| "In this study we analyzed the mechanisms underlying celecoxib-induced analgesia in a model of inflammatory pain in rats, using the intracerebroventricular (i." | 3.78 | Endogenous opioid and cannabinoid mechanisms are involved in the analgesic effects of celecoxib in the central nervous system. ( Bakhle, YS; Camêlo, VM; Dos Reis, WG; Faraco, A; Francischi, JN; Paiva-Lima, P; Rezende, RM, 2012) |
| "Celecoxib selectively affects genes and pathways involved in inflammation and malignant transformation in tumor but not normal tissues, this may assist in the development of safer and more effective chemopreventive agents." | 3.77 | Gene expression following exposure to celecoxib in humans: pathways of inflammation and carcinogenesis are activated in tumors but not normal tissues. ( Arber, N; Domany, E; Kazanov, D; Kraus, S; Naumov, I; Sagiv, E; Shapira, S; Sheffer, M, 2011) |
| " First, validate PEAP with Complete Freund's Adjuvant (CFA)-induced inflammation for the assessment of the affective component of pain using the reference analgesics celecoxib, diclofenac and duloxetine; fluoxetine and scopolamine were tested as negative controls." | 3.76 | Comparison of mechanical allodynia and the affective component of inflammatory pain in rats. ( Baker, SJ; Boyce-Rustay, JM; Decker, MW; Honore, P; Kohnken, R; Simler, GH; Wensink, EJ; Zhong, C, 2010) |
| " MSCs in osteogenesis were treated with COX-2 inhibitor (celecoxib and naproxen) in the absence or presence of interleukin-1β (IL-1β), which was used to induce inflammation." | 3.76 | The effects of COX-2 inhibitor during osteogenic differentiation of bone marrow-derived human mesenchymal stem cells. ( Han, CD; Kim, YH; Lee, JW; Paik, S; Yoo, JH; Yoon, DS, 2010) |
| " After treatment with celecoxib, the hypertension was attenuated (MAP=126±2 mm Hg) in obese rats without changes in HR." | 3.76 | Cox-2 inhibition attenuates cardiovascular and inflammatory aspects in monosodium glutamate-induced obese rats. ( Cecchini, R; Cunha, NV; de Abreu, SB; Grassiolli, S; Guarnier, FA; Martins-Pinge, MC; Mazzuco, TL; Panis, C; Pinge-Filho, P, 2010) |
| "Lornoxicam exhibits strong analgesic but weak antipyretic effects in rats with paw inflammation." | 3.75 | The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation. ( Arai, I; Futaki, N; Harada, M; Hashimoto, Y; Honma, Y; Hoshi, K; Nakaike, S; Sugimoto, M, 2009) |
| "Celecoxib has demonstrated an outstanding inhibitory effect on bladder cancer chemoprevention, which might be due to its expected anti-inflammatory actions, as well as by anti-proliferatory and antioxidant actions." | 3.75 | Anti-inflammatory, anti-proliferative and antioxidant profiles of selective cyclooxygenase-2 inhibition as chemoprevention for rat bladder carcinogenesis. ( Cunha, MF; Figueiredo, A; Garrido, P; Mota, A; Parada, B; Pinto, AF; Pinto, R; Reis, F; Sereno, J; Teixeira, F; Teixeira-Lemos, E, 2009) |
| "Substituted thiazoles with different structural features were synthesized and screened for their anti-inflammatory activity in acute carrageenin induced rat paw edema model and chronic formalin induced rat paw edema model." | 3.74 | 2-Amino-5-thiazolyl motif: a novel scaffold for designing anti-inflammatory agents of diverse structures. ( Franklin, PX; Nivsarkar, M; Padh, H; Pillai, AD; Rathod, PD; Sudarsanam, V; Vasu, KK; Yerande, S, 2008) |
| "32%), which is comparable to that of celecoxib in the carrageenan-induced rat paw edema method." | 3.74 | Synthesis and biological evaluation of 2-trifluoromethyl/sulfonamido-5,6-diaryl substituted imidazo[2,1-b]-1,3,4-thiadiazoles: a novel class of cyclooxygenase-2 inhibitors. ( Anand, K; Boreddy, TS; Gadad, AK; Noolvi, MN; Palkar, MB; Wagwade, J, 2008) |
| "Formation of reactive oxygen species and mitochondrial/lysosomal damages were significantly inhibited by both acetylsalicylic acid and celecoxib in hepatocytes of all pain- suffering animals." | 3.74 | Involvement of subcellular organelles in inflammatory pain-induced oxidative stress and apoptosis in the rat hepatocytes. ( Ahmadiani, A; Pourahmad, J; Rasekh, HR; Rezaei, M, 2008) |
| "The purpose of this study is to clarify involvement ratios between central and peripheral cyclooxygenase (COX)-2 in rat inflammatory pain models, by evaluating celecoxib and [6-chloro-2-(4-chlorobenzoyl)-1H-indol-3-yl]acetic acid (CIAA) on carrageenan-induced mechanical and thermal hyperalgesia." | 3.74 | Mathematical analysis of involvement ratio between central and peripheral COX-2 in rat pain models with two types of COX-2 inhibitors with different distribution, celecoxib and CIAA. ( Kita, Y; Murata, Y; Okumura, T; Sakakibara, A, 2008) |
| "The analgesic effects of celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, on formalin-induced pain are still controversial." | 3.73 | Analgesic effects of intrathecally administered celecoxib, a cyclooxygenase-2 inhibitor, in the tail flick test and the formalin test in rats. ( Nishiyama, T, 2006) |
| " Dose dependent percent inhibition of granuloma formation, exudate volume, total leukocyte count was observed in 4e (25, 50 and 100 mg/kg) and celecoxib (CAS 169590-42-5; 5 mg/kg) treated groups in the cotton pellet granuloma and granuloma pouch technique, respectively, in rats." | 3.73 | Evaluation of anti-inflammatory and analgesic activity of a new class of biphenyl analogs in animal models of inflammation. ( Bodhankar, SL; Kulkarni, VM; Rathi, BS; Wagh, NK, 2006) |
| "The effect of valeryl salicylate (VS), an inhibitor of cyclooxygenase-1 (COX-1), was evaluated in arachidonic acid or croton oil-induced ear oedema and carrageenan-induced paw oedema in mice." | 3.72 | Effects of valeryl salicylate, a COX-1 inhibitor, on models of acute inflammation in mice. ( Brum-Fernandes, AJ; Peters, RR; Ribeiro-do-Valle, RM; Siqueira-Junior, JM, 2003) |
| "The anti-inflammatory activity of fluoxetine, a selective serotonin reuptake inhibitor (SSRI), was studied on the carrageenan-induced paw inflammation in the rat." | 3.72 | Studies on the anti-inflammatory effect of fluoxetine in the rat. ( Abdel-Salam, OM; Arbid, MS; Baiuomy, AR, 2004) |
| " In this study, the authors examined whether a selective COX-2 inhibitor (celecoxib) reduces cerebral inflammation and edema after intracerebral hemorrhage (ICH), and whether functional recovery is sustained with longer treatment." | 3.72 | Celecoxib induces functional recovery after intracerebral hemorrhage with reduction of brain edema and perihematomal cell death. ( Chu, K; Han, SY; Jeong, SW; Jung, KH; Kim, M; Lee, ST; Roh, JK, 2004) |
| "To investigate the action of celecoxib (a selective COX-2 inhibitor) in a rat model of colitis induced by trinitrobenzene sulfonic acid (TNBS)." | 3.72 | Effects and mechanism of the selective COX-2 inhibitor, celecoxib, on rat colitis induced by trinitrobenzene sulfonic acid. ( Dong, XY; Lu, YM; Zhang, L, 2004) |
| "This study evaluates the action of celecoxib and rofecoxib, two selective cyclooxygenase-2 (COX-2) inhibitors in two acute models of inflammation, carrageenan (Cg)-induced rat pleurisy, and paw oedema formation." | 3.71 | Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation. ( Calixto, JB; Pinheiro, RM, 2002) |
| "The peripheral antinociceptive effect of the selective COX-2 inhibitor celecoxib in the formalin-induced inflammatory pain was compared with that of resveratrol (COX-1 inhibitor) and diclofenac (non-selective COX inhibitor)." | 3.71 | Comparison of the antinociceptive effect of celecoxib, diclofenac and resveratrol in the formalin test. ( Alonso-López, R; Asomoza-Espinosa, R; Castañeda-Hernández, G; Granados-Soto, V; Ortiz, MI; Torres-López, JE, 2002) |
| " Altogether 128 patients with knee osteoarthritis in the middle and early stage admitted to our hospital from January 2018 to July 2019 were selected and grouped into the control group (CG) (celecoxib tablet therapy) and the combination group (ComG) (celecoxib combined with glucosamine hydrochloride therapy)." | 3.01 | Effect of celecoxib combined with glucosamine hydrochloride in promoting the functional recovery and decreasing the inflammatory factor levels in patients with knee osteoarthritis. ( Ge, R; Yang, Z; Zhang, J, 2021) |
| "There was also no evidence that pre-treatment inflammation levels modified the effect of celecoxib augmentation versus placebo." | 3.01 | No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial. ( Baune, BT; Clark, SR; Fourrier, C; Hori, H; Louise, J; Mills, NT; Sampson, E; Schubert, KO, 2021) |
| "Standard dosing of the cyclooxygenase-2 inhibitor celecoxib slightly reduced perioperative cyclooxygenase activity during cancer surgery." | 2.84 | Impact of celecoxib on inflammation during cancer surgery: a randomized clinical trial. ( Hiller, JG; Ho, KM; Kuruvilla, N; Millen, R; Ramsay, R; Riedel, B; Sampurno, S, 2017) |
| "Celecoxib is an effective adjuvant therapy in the treatment of manic episodes (without psychotic features) of bipolar mood disorder." | 2.80 | Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double-blind, placebo-controlled trial. ( Akhondzadeh, S; Ameli, N; Arabzadeh, S; Farokhnia, M; Ghaleiha, A; Mohammadinejad, P; Rezaei, F; Zeinoddini, A, 2015) |
| "Celecoxib was concluded to reduce TNF-α levels significantly in the patients at the end of the study." | 2.79 | Effects of celecoxib on inflammatory markers in bipolar patients undergoing electroconvulsive therapy: a placebo-controlled, double-blind, randomised study. ( Abdollahi, A; Ahmadvand, A; Akhondzadeh, S; Artounian, V; Ghaeli, P; Kargar, M; Mojtahedzadeh, M; Yousefi, A, 2014) |
| "While inflammation is very significant in the abolition of pathogens and other causes of soreness, a protracted inflammatory procedure takes to outcomes in chronic disease that might finally affect in organ failure or damage." | 2.72 | Contemporary advances of cyclic molecules proposed for inflammation. ( Neha, K; Wakode, S, 2021) |
| "Pretreatment with ibuprofen, a nonspecific COX inhibitor, attenuated the febrile and systemic response to LPS and inhibited prostanoid biosynthesis." | 2.69 | Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. ( Burke, A; FitzGerald, GA; Habib, A; Kapoor, S; Lawson, JA; Mardini, IA; McAdam, BF, 2000) |
| " Low solubility and bioavailability issues related with celecoxib lead to the development and advancement in the discovery and research of some possible formulation administered either orally, topically or via transdermal route." | 2.66 | A journey of celecoxib from pain to cancer. ( Purohit, P; Saxena, P; Sharma, PK, 2020) |
| "Inflammation is a biological function which triggered after the mechanical tissue disruption or from the responses by the incidence of physical, chemical or biological negotiator in body." | 2.61 | Human disorders associated with inflammation and the evolving role of natural products to overcome. ( Kishore, N; Kumar, P; Shanker, K; Verma, AK, 2019) |
| "Celecoxib is an orally administered coxib." | 2.46 | [Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review]. ( Mateos, JL, 2010) |
| "Inflammation is closely linked with behavioral parameters such as exercise, sleep, alcohol abuse, and smoking, as well as with medical comorbidities including coronary artery disease, obesity and insulin resistance, osteoporosis, and pain." | 2.45 | Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. ( Goldstein, BI; Kemp, DE; McIntyre, RS; Soczynska, JK, 2009) |
| " Epidemiologic data showed that chronic intake of traditional nonsteroidal anti-inflammatory drugs (NSAIDs) could reduce the incidence of colorectal cancer." | 2.42 | Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications. ( Chen, BD; Chou, TH; Chu, AJ, 2004) |
| " Moreover, some epidemiologic and pilot clinical studies have proven that long-term administration of anti-inflammatory drugs have a protective effect on the onset of AD." | 2.41 | Alzheimer's disease, inflammation and non-steroidal anti-inflammatory drugs. ( Ferencik, M; Novak, M; Rovensky, J; Rybar, I, 2001) |
| "Prostatic inflammation is the driving force in benign prostatic hyperplasia (BPH)." | 1.91 | Cyclooxygenase-2 activates EGFR-ERK1/2 pathway via PGE2-mediated ADAM-17 signaling in testosterone-induced benign prostatic hyperplasia. ( Abdel-Fattah, MM; Abo-El Fetoh, ME; Afify, H; Mohamed, WR; Ramadan, LAA, 2023) |
| "Celecoxib was administered for 21 consecutive days, starting the day after hydrocephalus induction and continuing until the end of the experimental period." | 1.91 | Celecoxib attenuates neuroinflammation, reactive astrogliosis and promotes neuroprotection in young rats with experimental hydrocephalus. ( Covas da Silva, S; da Silva Beggiora Marques, P; da Silva Lopes, L; Dutra, LA; Dutra, M; Funo de Souza, SN; Machado, HR; Oliveira Amaral, I; Volpon Santos, M, 2023) |
| "The treatment of chronic Achilles tendonitis (AT) often requires prolonged therapy and invasive therapeutic methods such as surgery or therapeutic endoscopy." | 1.72 | Long-term anti-inflammatory effects of injectable celecoxib nanoparticle hydrogels for Achilles tendon regeneration. ( Hong, KH; Kim, J; Kim, SE; Kim, YM; Seo, BB; Song, SC, 2022) |
| "Celecoxib (CLB) is a highly hydrophobic selective cyclo-oxygenase inhibitor with high plasma protein binding and undergoes extensive hepatic metabolism." | 1.72 | Development of stealth liposomal formulation of celecoxib: In vitro and in vivo evaluation. ( Alqahtani, A; Ather, H; Atiya, A; Begum, MY; Ghazwani, M; Hani, U; M Osmani, RA; Rahamathulla, M; Siddiqua, A, 2022) |
| " Nonetheless, the long-term administration of both medications might result in osteonecrosis of the knee due to repeated injections of steroids and side effects in the gastrointestinal and cardiovascular systems." | 1.72 | Dexamethasone microspheres and celecoxib microcrystals loaded into injectable gels for enhanced knee osteoarthritis therapy. ( Chen, J; Chen, W; Fang, W; Hu, Q; Li, W; Qiu, L; Yang, F; Yang, M, 2022) |
| "Mechanical allodynia, heat hyperalgesia, biased weight-bearing, and hindpaw thickness were assessed 0." | 1.62 | Antinociception produced by nonsteroidal anti-inflammatory drugs in female vs male rats. ( Britch, SC; Craft, RM; Hewitt, KA, 2021) |
| "The animal models of liver fibrosis induced with TAA were established in rats and in intestinal epithelial-specific COX-2 knockout mice." | 1.62 | Inhibition of cyclooxygenase-2 enhanced intestinal epithelial homeostasis via suppressing β-catenin signalling pathway in experimental liver fibrosis. ( Gao, J; Ma, X; Tai, Y; Tang, C; Tang, S; Tong, H; Zhang, L; Zhao, C, 2021) |
| "Treatment of Celecoxib decreased DON-induced translocation of Protein Kinase C isozymes (α,ε,γ), demonstrating the role of PKC in DON-mediated biochemical and molecular alterations responsible for its dermal toxicity." | 1.56 | Celecoxib reduces Deoxynivalenol induced proliferation, inflammation and protein kinase C translocation via modulating downstream targets in mouse skin. ( Chaturvedi, S; Dewangan, J; Divakar, A; Kumar, S; Mandal, P; Mishra, S; Rath, SK; Srivastava, S; Tripathi, A; Wahajuddin, M, 2020) |
| " The relative bioavailability (BA) of the M3 and SD6 formulations was also significantly improved as oral bioavailability (167." | 1.56 | Therapeutic effects of celecoxib polymeric systems in rat models of inflammation and adjuvant-induced rheumatoid arthritis. ( Ahn, JB; Choi, JS; Heo, KS; Lee, DH; Myung, CS; Park, JS; Sim, S, 2020) |
| "Inflammation has a key role in AV pathological remodeling; hence, anti-inflammatory therapy has been proposed as a strategy to prevent CAVD." | 1.56 | COX-2 Is Downregulated in Human Stenotic Aortic Valves and Its Inhibition Promotes Dystrophic Calcification. ( Antonucci, A; Campo, G; Cimaglia, P; Ferrari, R; Fortini, F; Marracino, L; Moscarelli, M; Rizzo, P; Tonet, E; Vieceli Dalla Sega, F, 2020) |
| "Depression is considered a neuropsychiatric condition which is associated with neuronal injury within specific brain regions." | 1.51 | COX-2 inhibition rescues depression-like behaviors via suppressing glial activation, oxidative stress and neuronal apoptosis in rats. ( Fan, C; Feng, YB; Li, Y; Shen, J; Song, Q; Wang, L; Wang, P; Yu, SY, 2019) |
| "The progression and metastasis of pancreatic ductal adenocarcinoma (PDAC) is highly dependent on the tumour microenvironment." | 1.51 | Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages. ( Bai, X; Chen, Q; Chen, Y; Dang, X; Fu, Q; Liang, T; Lou, Y; Wang, J; Wei, T; Yang, J; Ye, M; Zhang, J; Zhang, Q; Zhang, X, 2019) |
| "Inflammation is closely related to neoplastic development and the release of inflammatory cytokines and chemokines represents a crucial event in this relationship." | 1.51 | Nonsteroidal Anti-inflammatory Drugs Modulate Gene Expression of Inflammatory Mediators in Oral Squamous Cell Carcinoma. ( Antunes, DM; Corrêa, L; DE Oliveira, APL; Duarte, CME; Fernandes, KPS; Guimarães, DM; Miguita, L; Nunes, FD; Rodrigues, MFSD, 2019) |
| " The prostate tissue penetration and related pharmacokinetic parameters were evaluated by non-compartmental analysis." | 1.48 | Penetration and pharmacokinetics of non-steroidal anti-inflammatory drugs in rat prostate tissue. ( Radhakrishnan, J; Radhakrishnan, R; Yellepeddi, VK, 2018) |
| "Celecoxib (CXB) is a widely used anti-inflammatory drug that also acts as a chemopreventive agent against several types of cancer, including skin cancer." | 1.48 | Liquid Crystalline Systems Based on Glyceryl Monooleate and Penetration Enhancers for Skin Delivery of Celecoxib: Characterization, In Vitro Drug Release, and In Vivo Studies. ( Borgheti-Cardoso, LN; Dante, MCL; Fantini, MCA; Lara, MG; Medina, WSG; Pierre, MBR; Praça, FSG, 2018) |
| "Ciprofloxacin and celecoxib were used in combination to regulate S." | 1.48 | Combination treatment of celecoxib and ciprofloxacin attenuates live S. aureus induced oxidative damage and inflammation in murine microglia via regulation of cytokine balance. ( Bishayi, B; Dey, R; Sultana, S, 2018) |
| "However, the role of COX-2 in epithelial ovarian cancer (EOC), and its mechanistic details, remain poorly understood." | 1.48 | COX-2 inhibition by celecoxib in epithelial ovarian cancer attenuates E-cadherin suppression through reduced Snail nuclear translocation. ( Li, CH; Li, XW; Wang, QY; Wang, YP, 2018) |
| "Kartogenin (KGN) is a small drug-like molecule that induces chondrogenesis in mesenchymal stem cells (MSCs)." | 1.48 | Kartogenin inhibits pain behavior, chondrocyte inflammation, and attenuates osteoarthritis progression in mice through induction of IL-10. ( Cho, KH; Cho, ML; Choi, J; Jung, K; Kim, SJ; Kwon, JY; Lee, CY; Lee, SH; Na, HS; Park, SH; Shin, DY, 2018) |
| "We tested whether this parameter and tactile allodynia, the standard pain measure in preclinical studies, show parallels in their response to analgesics and basic mechanisms." | 1.46 | Grip strength in mice with joint inflammation: A rheumatology function test sensitive to pain and analgesia. ( Cañizares, FJ; Cobos, EJ; Entrena, JM; Fernández-Segura, E; Montilla-García, Á; Perazzoli, G; Portillo-Salido, E; Tejada, MÁ, 2017) |
| "Chronic inflammation has been directly linked to cancer progression." | 1.43 | Celecoxib and fish oil: a combination strategy for decreased inflammatory mediators in early stages of experimental mammary cancer. ( Agnihotri, N; Bhatnagar, A; Negi, AK, 2016) |
| "Inflammation is a potent promoter of tumor metastasis." | 1.42 | Lipopolysaccharide induces inflammation and facilitates lung metastasis in a breast cancer model via the prostaglandin E2-EP2 pathway. ( Bi, Y; Han, M; Jiang, M; Li, S; Xu, J; Xu, X, 2015) |
| " The objective of this study is to investigate the effect of FLP alone or in combination with celecoxib in the prevention of lung cancer progression by Cyclooxygenase (Cox)-2 mediated tumor inflammatory microenvironment in vivo." | 1.42 | Anti-tumor enhancement of Fei-Liu-Ping ointment in combination with celecoxib via cyclooxygenase-2-mediated lung metastatic inflammatory microenvironment in Lewis lung carcinoma xenograft mouse model. ( Bao, Y; Gao, Y; Guo, Q; He, S; Hirasaki, Y; Hou, W; Hua, B; Li, C; Li, W; Liu, R; Pei, Y; Qi, X; Zhang, Y; Zheng, H, 2015) |
| "Rheumatoid arthritis is a chronic inflammatory disease characterized by overproduction of inflammatory mediators along with undermined oxidative defensive mechanisms." | 1.40 | Evening primrose oil and celecoxib inhibited pathological angiogenesis, inflammation, and oxidative stress in adjuvant-induced arthritis: novel role of angiopoietin-1. ( El-Azab, MF; El-Sayed, RM; Moustafa, YM, 2014) |
| "In the comparison of carcinogenesis, the percentage of normal tissue (i." | 1.40 | Combinational chemoprevention effect of celecoxib and an oral antiangiogenic LHD4 on colorectal carcinogenesis in mice. ( Alam, F; Byun, Y; Chung, SW; Jeon, OC; Kim, JY; Kim, SY; Park, J; Son, WC, 2014) |
| "Human hepatoma cell lines were treated with lipopolysaccharide (LPS) or cyclooxygenase-2 inhibitor, Celecoxib, and in vitro proliferation, apoptosis, and cell cycle progression were assessed." | 1.39 | Proinflammatory conditions promote hepatocellular carcinoma onset and progression via activation of Wnt and EGFR signaling pathways. ( Bai, L; Mao, ZY; Su, D; Wang, LJ; Zhang, T, 2013) |
| "Celecoxib is a selective cyclooxygenase-2 (COX2) inhibitor." | 1.39 | A trifluoromethyl analogue of celecoxib exerts beneficial effects in neuroinflammation. ( Alloza, I; Chiba, A; Di Penta, A; Miyake, S; Vandenbroeck, K; Villoslada, P; Wyssenbach, A; Yamamura, T, 2013) |
| "Treatment with celecoxib had effects on inflammation response and reduced cancer metastasis." | 1.39 | Primary tumor regulates the pulmonary microenvironment in melanoma carcinoma model and facilitates lung metastasis. ( Bi, Y; Han, M; Jia, J; Jiang, M; Liu, Q; Xu, J; Xu, X, 2013) |
| "Benzothiazole amides were identified as TRPV1 antagonists from high throughput screening using recombinant human TRPV1 receptor and structure-activity relationships were explored to pinpoint key pharmacophore interactions." | 1.38 | Potent and orally efficacious benzothiazole amides as TRPV1 antagonists. ( Besidski, Y; Brown, W; Bylund, J; Dabrowski, M; Dautrey, S; Griffin, AM; Harter, M; Horoszok, L; Hu, Y; Johnson, D; Johnstone, S; Jones, P; Kers, I; Kolmodin, K; Labarre, M; Labrecque, D; Laird, J; Leclerc, S; Lundström, T; Martino, J; Maudet, M; Munro, A; Nylöf, M; Penwell, A; Rotticci, D; Slaitas, A; Sundgren-Andersson, A; Svensson, M; Terp, G; Villanueva, H; Walpole, C; Zemribo, R, 2012) |
| "Quinolinic acid (300 nmol) was administered intrastriatally into the striatum to induce Huntington's disease-like alteration." | 1.37 | Suppressing inflammatory cascade by cyclo-oxygenase inhibitors attenuates quinolinic acid induced Huntington's disease-like alterations in rats. ( Kalonia, H; Kumar, A, 2011) |
| "The sites of secondary metastasis and the associated inflammatory microenvironment were evaluated." | 1.37 | Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer. ( Ghosh, S; Gruber, HE; Mukherjee, P; Pathangey, LB; Roy, LD; Tinder, TL, 2011) |
| " PGE(2) levels in mice dosed with R-2-phenylpropionic acid were elevated." | 1.36 | Role of COX-2 in nonsteroidal anti-inflammatory drug enteropathy in rodents. ( Bjarnason, IT; Hotz-Behofsits, C; Simpson, RJ; Walley, M, 2010) |
| "Chronic airway inflammation is a characteristic feature of destructive cigarette smoking (CS)-induced lung disease, particularly in patients with emphysema." | 1.36 | Anti-inflammatory effects of celecoxib in rat lungs with smoke-induced emphysema. ( Cho, YJ; Huh, JW; Hwang, YS; Jeon, BT; Kim, HJ; Kim, JH; Lee, JD; Lee, JH; Lee, SD; Nizamudtinova, IT; Oh, YM; Roh, GS; Yi, CO, 2010) |
| "Inflammation was induced in one hind paw of rats by intraplantar injection of carrageenan (250 μg)." | 1.36 | Is the sulphonamide radical in the celecoxib molecule essential for its analgesic activity? ( Bakhle, YS; de Francischi, JN; dos Reis, WG; Ferreira-Alves, DL; Gassani, BC; Paiva-Lima, P; Rezende, RM, 2010) |
| "Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2)." | 1.36 | Celecoxib induces tolerance in a model of peripheral inflammatory pain in rats. ( Bakhle, YS; Camêlo, VM; de Francischi, JN; Dos Reis, WG; Paiva-Lima, P; Rezende, RM, 2010) |
| "Celecoxib was administered at the rate of 3 mg/kg per day, loxoprofen at 3 mg/kg per day, and SC-58560 at 10 mg/kg per day." | 1.35 | Micro-CT imaging analysis for the effect of celecoxib, a cyclooxygenase-2 inhibitor, on inflammatory bone destruction in adjuvant arthritis rats. ( Kimoto, A; Miyata, K; Noguchi, M; Sasamata, M, 2008) |
| "We conclude for the first time that prostate cancer induced by MNU plus testosterone partly involves mediators of inflammation which could trigger the process of carcinogenesis and cause loss of apoptosis." | 1.35 | Inflammatory processes of prostate tissue microenvironment drive rat prostate carcinogenesis: preventive effects of celecoxib. ( Bosland, MC; Horton, L; Narayanan, BA; Narayanan, NK; Nargi, D; Reddy, BS, 2009) |
| "Celecoxib is a selective inhibitor of cyclooxygenase-2 (COX-2) and blocks prostaglandin (PG) biosynthesis associated with inflammatory conditions." | 1.35 | The analgesic actions of centrally administered celecoxib are mediated by endogenous opioids. ( Bakhle, YS; de Francischi, JN; Dos Reis, WG; Duarte, ID; Lima, PP; Rezende, RM, 2009) |
| "Oral mucositis is a severe, dose-limiting side effect of radio(chemo)therapy for head and neck tumors." | 1.35 | Effect of selective inhibitors of inflammation on oral mucositis: preclinical studies. ( Dörr, W; Haagen, J; Krohn, H; Röllig, S; Schmidt, M; Wolfram, K, 2009) |
| " Increasing evidence suggests that an inflammatory reaction accompanies the pathological processes caused by Cyclooxygenase (COX) seen in many neurodegenerative disorders, including PD and according to the recent researches chronic use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) decreases the risk of PD in human." | 1.34 | Effects of aspirin and celecoxib on rigidity in a rat model of Parkinson's disease. ( Abid, KM; Ardestani, MS; Hemmati, A; Mehrab, H; Moghaddam, HF; Nazari, Z, 2007) |
| " Recently, cardiotoxic effects associated with conventional modes of delivery of celecoxib have made it pertinent to develop alternate dosage forms capable of selectively delivering the drug topically to affected joints." | 1.34 | Niosomal gel for site-specific sustained delivery of anti-arthritic drug: in vitro-in vivo evaluation. ( Jain, S; Kaur, K; Sapra, B; Tiwary, AK, 2007) |
| "2% at 1 and 2h after dosing (P<0." | 1.32 | The anti-inflammatory effects of the phosphodiesterase inhibitor pentoxifylline in the rat. ( Abdel-Salam, OM; Arbid, MS; Baiuomy, AR; El-Shenawy, SM, 2003) |
| "Celecoxib and aspirin were ineffective at preventing lung tumorigenesis in a two-stage carcinogenesis protocol in which 3-methylcholanthrene administration is followed by chronic BHT." | 1.31 | Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice. ( Barrett, BS; Bauer, AK; Dwyer-Nield, LD; Kisley, LR; Malkinson, AM; Thompson, DC, 2002) |
| "2." | 1.31 | Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. ( Bakhle, YS; Chaves, CT; Ferreira-Alves, DL; Francischi, JN; Lima, AS; Moura, AC; Rocha, OA, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (1.66) | 18.2507 |
| 2000's | 66 (27.39) | 29.6817 |
| 2010's | 119 (49.38) | 24.3611 |
| 2020's | 52 (21.58) | 2.80 |
| Authors | Studies |
|---|---|
| Feixas, J | 1 |
| Jiménez, JM | 1 |
| Godessart, N | 1 |
| Puig, C | 1 |
| Soca, L | 1 |
| Crespo, MI | 1 |
| Almansa, C | 1 |
| Alfón, J | 1 |
| de Arriba, AF | 1 |
| Cavalcanti, FL | 1 |
| Escamilla, I | 1 |
| Gómez, LA | 1 |
| Miralles, A | 1 |
| Soliva, R | 1 |
| Bartrolí, J | 1 |
| Carceller, E | 1 |
| Merlos, M | 1 |
| García-Rafanell, J | 1 |
| Khanapure, SP | 2 |
| Garvey, DS | 2 |
| Young, DV | 2 |
| Ezawa, M | 1 |
| Earl, RA | 2 |
| Gaston, RD | 1 |
| Fang, X | 1 |
| Murty, M | 1 |
| Martino, A | 1 |
| Shumway, M | 1 |
| Trocha, M | 1 |
| Marek, P | 1 |
| Tam, SW | 1 |
| Janero, DR | 2 |
| Letts, LG | 2 |
| Augustyniak, ME | 1 |
| Martino, AM | 1 |
| Murty, MG | 1 |
| Schwalb, DJ | 1 |
| Shumway, MJ | 1 |
| Trocha, AM | 1 |
| Zemtseva, IS | 1 |
| Franklin, PX | 1 |
| Pillai, AD | 1 |
| Rathod, PD | 1 |
| Yerande, S | 1 |
| Nivsarkar, M | 2 |
| Padh, H | 1 |
| Vasu, KK | 2 |
| Sudarsanam, V | 2 |
| Gadad, AK | 1 |
| Palkar, MB | 1 |
| Anand, K | 1 |
| Noolvi, MN | 1 |
| Boreddy, TS | 1 |
| Wagwade, J | 1 |
| Abdellatif, KR | 5 |
| Chowdhury, MA | 3 |
| Dong, Y | 3 |
| Knaus, EE | 4 |
| Koeberle, A | 1 |
| Zettl, H | 1 |
| Greiner, C | 1 |
| Wurglics, M | 1 |
| Schubert-Zsilavecz, M | 1 |
| Werz, O | 1 |
| Rahman, M | 1 |
| Das, D | 1 |
| Suresh, MR | 1 |
| Swarbrick, ME | 1 |
| Beswick, PJ | 1 |
| Gleave, RJ | 1 |
| Green, RH | 1 |
| Bingham, S | 1 |
| Bountra, C | 1 |
| Carter, MC | 1 |
| Chambers, LJ | 1 |
| Chessell, IP | 1 |
| Clayton, NM | 1 |
| Collins, SD | 1 |
| Corfield, JA | 1 |
| Hartley, CD | 1 |
| Kleanthous, S | 1 |
| Lambeth, PF | 1 |
| Lucas, FS | 1 |
| Mathews, N | 1 |
| Naylor, A | 1 |
| Page, LW | 1 |
| Payne, JJ | 1 |
| Pegg, NA | 1 |
| Price, HS | 1 |
| Skidmore, J | 1 |
| Stevens, AJ | 1 |
| Stocker, R | 1 |
| Stratton, SC | 1 |
| Stuart, AJ | 1 |
| Wiseman, JO | 1 |
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Besidski, Y | 1 |
| Brown, W | 1 |
| Bylund, J | 1 |
| Dabrowski, M | 1 |
| Dautrey, S | 1 |
| Harter, M | 1 |
| Horoszok, L | 1 |
| Hu, Y | 1 |
| Johnson, D | 1 |
| Johnstone, S | 1 |
| Jones, P | 1 |
| Leclerc, S | 1 |
| Kolmodin, K | 1 |
| Kers, I | 1 |
| Labarre, M | 1 |
| Labrecque, D | 1 |
| Laird, J | 1 |
| Lundström, T | 1 |
| Martino, J | 1 |
| Maudet, M | 1 |
| Munro, A | 1 |
| Nylöf, M | 1 |
| Penwell, A | 1 |
| Rotticci, D | 1 |
| Slaitas, A | 1 |
| Sundgren-Andersson, A | 1 |
| Svensson, M | 1 |
| Terp, G | 1 |
| Villanueva, H | 1 |
| Walpole, C | 1 |
| Zemribo, R | 1 |
| Griffin, AM | 1 |
| Gaba, M | 1 |
| Singh, S | 3 |
| Mohan, C | 1 |
| Haider, S | 1 |
| Alam, MS | 1 |
| Hamid, H | 1 |
| Shafi, S | 1 |
| Dhulap, A | 1 |
| Hussain, F | 1 |
| Alam, P | 1 |
| Umar, S | 1 |
| Pasha, MA | 1 |
| Bano, S | 1 |
| Nazreen, S | 1 |
| Ali, Y | 1 |
| Kharbanda, C | 1 |
| Moawad, A | 1 |
| Parsons, WH | 1 |
| Calvo, RR | 1 |
| Cheung, W | 1 |
| Lee, YK | 1 |
| Patel, S | 1 |
| Liu, J | 1 |
| Youngman, MA | 1 |
| Dax, SL | 1 |
| Stone, D | 1 |
| Qin, N | 1 |
| Hutchinson, T | 1 |
| Lubin, ML | 1 |
| Zhang, SP | 1 |
| Finley, M | 1 |
| Liu, Y | 4 |
| Brandt, MR | 1 |
| Flores, CM | 1 |
| Player, MR | 1 |
| Su, XD | 1 |
| Guo, RH | 1 |
| Li, HX | 1 |
| Ma, JY | 1 |
| Kim, YR | 1 |
| Kim, YH | 2 |
| Yang, SY | 1 |
| Singh, P | 2 |
| Kaur, S | 2 |
| Kumari, P | 2 |
| Kaur, B | 1 |
| Kaur, M | 1 |
| Singh, G | 1 |
| Bhatti, R | 2 |
| Bhatti, M | 1 |
| Marín-Ocampo, L | 1 |
| Veloza, LA | 1 |
| Abonia, R | 1 |
| Sepúlveda-Arias, JC | 1 |
| AlFadly, ED | 1 |
| Elzahhar, PA | 1 |
| Tramarin, A | 1 |
| Elkazaz, S | 1 |
| Shaltout, H | 1 |
| Abu-Serie, MM | 1 |
| Janockova, J | 1 |
| Soukup, O | 1 |
| Ghareeb, DA | 1 |
| El-Yazbi, AF | 1 |
| Rafeh, RW | 1 |
| Bakkar, NZ | 1 |
| Kobeissy, F | 1 |
| Iriepa, I | 1 |
| Moraleda, I | 1 |
| Saudi, MNS | 1 |
| Bartolini, M | 1 |
| Belal, ASF | 1 |
| Kishore, N | 1 |
| Kumar, P | 1 |
| Shanker, K | 1 |
| Verma, AK | 1 |
| Kaur, J | 1 |
| Zheng, XJ | 1 |
| Li, CS | 1 |
| Cui, MY | 1 |
| Song, ZW | 1 |
| Bai, XQ | 1 |
| Liang, CW | 1 |
| Wang, HY | 1 |
| Zhang, TY | 1 |
| Zheng, Y | 2 |
| Zhang, YL | 1 |
| Li, Z | 2 |
| Shi, W | 2 |
| Ji, YR | 1 |
| Guo, YH | 1 |
| Huang, C | 2 |
| Sun, GP | 1 |
| Li, J | 3 |
| Sagar, SR | 1 |
| Singh, DP | 1 |
| Das, RD | 1 |
| Panchal, NB | 1 |
| Neha, K | 1 |
| Wakode, S | 1 |
| Zhang, J | 3 |
| Ge, R | 1 |
| Yang, Z | 1 |
| Ghosh, S | 2 |
| Naeem, M | 1 |
| Iqbal, T | 1 |
| Nawaz, Z | 1 |
| Hussain, S | 1 |
| Desind, SZ | 1 |
| Iacona, JR | 1 |
| Yu, CY | 1 |
| Mitrofanova, A | 1 |
| Lutz, CS | 1 |
| Kim, J | 1 |
| Seo, BB | 1 |
| Hong, KH | 1 |
| Kim, SE | 1 |
| Kim, YM | 1 |
| Song, SC | 1 |
| Begum, MY | 1 |
| M Osmani, RA | 1 |
| Alqahtani, A | 1 |
| Ghazwani, M | 1 |
| Hani, U | 1 |
| Ather, H | 1 |
| Atiya, A | 1 |
| Rahamathulla, M | 1 |
| Siddiqua, A | 1 |
| Fang, W | 1 |
| Yang, F | 1 |
| Li, W | 2 |
| Hu, Q | 1 |
| Chen, W | 4 |
| Yang, M | 1 |
| Chen, J | 1 |
| Qiu, L | 1 |
| Zhang, L | 4 |
| Li, M | 1 |
| Wang, W | 1 |
| Yu, W | 1 |
| Liu, H | 1 |
| Wang, K | 1 |
| Chang, M | 1 |
| Deng, C | 2 |
| Ji, Y | 1 |
| Shen, Y | 1 |
| Qi, L | 1 |
| Sun, H | 1 |
| Kaur, R | 1 |
| Desai, D | 1 |
| Amin, S | 1 |
| Raza, K | 1 |
| Bhalla, A | 1 |
| Yadav, P | 1 |
| Kaushal, N | 1 |
| Tu, L | 1 |
| Zhao, M | 1 |
| Wang, X | 1 |
| Kong, Q | 1 |
| Chen, Z | 1 |
| Wei, Q | 1 |
| Li, Q | 1 |
| Yu, Q | 1 |
| Ye, Z | 1 |
| Cao, S | 1 |
| Lin, Z | 1 |
| Liao, Z | 1 |
| Lv, Q | 1 |
| Qi, J | 1 |
| Jin, O | 1 |
| Pan, Y | 1 |
| Gu, J | 1 |
| Syrova, GO | 1 |
| Savelieva, OV | 1 |
| Tishakova, TS | 1 |
| Lukіаnova, LV | 1 |
| Yasen, M | 3 |
| Wang, H | 3 |
| Zhuang, C | 3 |
| Wang, Z | 3 |
| Lu, S | 3 |
| Jiang, L | 3 |
| Lin, H | 3 |
| Tellegen, AR | 3 |
| Rudnik-Jansen, I | 3 |
| Utomo, L | 2 |
| Versteeg, S | 2 |
| Beukers, M | 2 |
| Maarschalkerweerd, R | 2 |
| van Zuilen, D | 2 |
| van Klaveren, NJ | 2 |
| Houben, K | 2 |
| Teske, E | 2 |
| van Weeren, PR | 2 |
| Karssemakers-Degen, N | 2 |
| Mihov, G | 3 |
| Thies, J | 2 |
| Eijkelkamp, N | 2 |
| Creemers, LB | 3 |
| Meij, BP | 3 |
| Tryfonidou, MA | 3 |
| Abo-El Fetoh, ME | 1 |
| Abdel-Fattah, MM | 1 |
| Mohamed, WR | 1 |
| Ramadan, LAA | 1 |
| Afify, H | 1 |
| Jahani, V | 1 |
| Yazdani, M | 1 |
| Badiee, A | 1 |
| Jaafari, MR | 1 |
| Arabi, L | 1 |
| Guo, Y | 2 |
| Jiang, D | 1 |
| Mai, Z | 1 |
| Chen, Y | 3 |
| Li, T | 1 |
| Gao, G | 1 |
| Liu, K | 1 |
| Zhen, W | 1 |
| Bai, D | 1 |
| Tan, H | 1 |
| He, X | 1 |
| Li, Y | 3 |
| Zhang, Y | 7 |
| Ito, K | 1 |
| Zhang, B | 1 |
| Ma, Y | 1 |
| Ganai, SA | 1 |
| Rajamanikandan, S | 1 |
| Shah, BA | 1 |
| Lone, A | 1 |
| Arwa, F | 1 |
| Malik, FA | 1 |
| Dutra, M | 1 |
| Covas da Silva, S | 1 |
| da Silva Beggiora Marques, P | 1 |
| Oliveira Amaral, I | 1 |
| Funo de Souza, SN | 1 |
| Dutra, LA | 2 |
| Volpon Santos, M | 1 |
| Machado, HR | 1 |
| da Silva Lopes, L | 1 |
| Carranza, C | 1 |
| Sartillo-Mendoza, LG | 1 |
| Carreto-Binaghi, LE | 1 |
| Muñoz-Torrico, M | 1 |
| Guzmán-Beltrán, S | 1 |
| Torres, M | 1 |
| Gonzalez, Y | 1 |
| Juárez, E | 1 |
| Song, Q | 1 |
| Feng, YB | 1 |
| Wang, L | 1 |
| Shen, J | 1 |
| Fan, C | 1 |
| Wang, P | 1 |
| Yu, SY | 1 |
| Chen, Q | 3 |
| Wang, J | 1 |
| Zhang, Q | 1 |
| Lou, Y | 1 |
| Yang, J | 1 |
| Wei, T | 1 |
| Fu, Q | 1 |
| Ye, M | 1 |
| Zhang, X | 1 |
| Dang, X | 1 |
| Liang, T | 1 |
| Bai, X | 1 |
| Xu, T | 1 |
| Ghazala, RA | 1 |
| El Medney, A | 1 |
| Meleis, A | 1 |
| Mohie El Dien, P | 1 |
| Samir, H | 1 |
| Saxena, P | 1 |
| Sharma, PK | 1 |
| Purohit, P | 1 |
| Philpott, HT | 1 |
| McDougall, JJ | 1 |
| Oliveira, DH | 1 |
| Sousa, FSS | 1 |
| Birmann, PT | 1 |
| Alves, D | 1 |
| Jacob, RG | 1 |
| Savegnago, L | 1 |
| Liu, L | 1 |
| Karagoz, H | 1 |
| Herneisey, M | 1 |
| Zor, F | 1 |
| Komatsu, T | 1 |
| Loftus, S | 1 |
| Janjic, BM | 1 |
| Gorantla, VS | 1 |
| Janjic, JM | 2 |
| Ouyang, N | 1 |
| Zhao, Y | 1 |
| Chen, L | 2 |
| Fang, B | 1 |
| Dai, J | 1 |
| Shen, G | 1 |
| Mishra, S | 1 |
| Srivastava, S | 1 |
| Divakar, A | 1 |
| Mandal, P | 1 |
| Dewangan, J | 1 |
| Chaturvedi, S | 1 |
| Wahajuddin, M | 1 |
| Kumar, S | 2 |
| Tripathi, A | 1 |
| Rath, SK | 1 |
| Berk, M | 1 |
| Vieta, E | 1 |
| Dean, OM | 1 |
| El-Hazek, RMM | 1 |
| El-Sabbagh, WA | 1 |
| El-Hazek, RM | 2 |
| El-Gazzar, MG | 1 |
| An, Y | 1 |
| Fan, M | 1 |
| Salgado, C | 1 |
| Guénée, L | 1 |
| Černý, R | 1 |
| Allémann, E | 1 |
| Jordan, O | 1 |
| Araújo, PHF | 1 |
| Ramos, RS | 1 |
| da Cruz, JN | 1 |
| Silva, SG | 1 |
| Ferreira, EFB | 1 |
| de Lima, LR | 1 |
| Macêdo, WJC | 1 |
| Espejo-Román, JM | 1 |
| Campos, JM | 1 |
| Santos, CBR | 1 |
| Raison, CL | 1 |
| Choi, JS | 1 |
| Lee, DH | 1 |
| Ahn, JB | 1 |
| Sim, S | 1 |
| Heo, KS | 1 |
| Myung, CS | 1 |
| Park, JS | 1 |
| Li, X | 1 |
| Zhou, K | 1 |
| Zhou, M | 1 |
| Xia, K | 1 |
| Xu, Y | 1 |
| Sun, X | 1 |
| Zhu, Y | 1 |
| Cui, C | 1 |
| Jaisin, Y | 1 |
| Ratanachamnong, P | 1 |
| Wongsawatkul, O | 1 |
| Watthammawut, A | 1 |
| Malaniyom, K | 1 |
| Natewong, S | 1 |
| Vieceli Dalla Sega, F | 1 |
| Fortini, F | 1 |
| Cimaglia, P | 1 |
| Marracino, L | 1 |
| Tonet, E | 1 |
| Antonucci, A | 1 |
| Moscarelli, M | 1 |
| Campo, G | 1 |
| Rizzo, P | 1 |
| Ferrari, R | 1 |
| Craft, RM | 1 |
| Hewitt, KA | 1 |
| Britch, SC | 1 |
| Tang, S | 2 |
| Huang, Z | 1 |
| Jiang, J | 1 |
| Gao, J | 2 |
| Zhao, C | 2 |
| Tai, Y | 2 |
| Ma, X | 2 |
| Ye, Y | 1 |
| Gan, C | 1 |
| Su, W | 1 |
| Jia, X | 1 |
| Liu, R | 2 |
| Wu, H | 1 |
| Tang, C | 2 |
| Yin, X | 1 |
| Wen, Y | 1 |
| Yang, Y | 1 |
| Chen, H | 1 |
| Prabhakaran, J | 1 |
| Molotkov, A | 1 |
| Mintz, A | 1 |
| Mann, JJ | 1 |
| Sheta, NM | 1 |
| Boshra, SA | 1 |
| Tong, H | 1 |
| Baune, BT | 1 |
| Sampson, E | 1 |
| Louise, J | 1 |
| Hori, H | 1 |
| Schubert, KO | 1 |
| Clark, SR | 1 |
| Mills, NT | 1 |
| Fourrier, C | 1 |
| Abdelhady, SA | 1 |
| Ali, MA | 1 |
| Al-Shafie, TA | 1 |
| Abdelmawgoud, EM | 1 |
| Yacout, DM | 1 |
| El-Mas, MM | 1 |
| Brox, R | 1 |
| Hackstein, H | 1 |
| Ko, CJ | 1 |
| Lan, SW | 1 |
| Lu, YC | 1 |
| Cheng, TS | 1 |
| Lai, PF | 1 |
| Tsai, CH | 1 |
| Hsu, TW | 1 |
| Lin, HY | 1 |
| Shyu, HY | 1 |
| Wu, SR | 1 |
| Lin, HH | 1 |
| Hsiao, PW | 1 |
| Chen, CH | 2 |
| Huang, HP | 1 |
| Lee, MS | 1 |
| Gao, GM | 1 |
| Li, YM | 1 |
| Zheng, XL | 1 |
| Jiang, DB | 1 |
| Zhang, LL | 1 |
| Xu, PH | 1 |
| Liu, SY | 1 |
| Zheng, ZH | 1 |
| Kan, QC | 1 |
| Baek, JS | 1 |
| Yeo, EW | 1 |
| Lee, YH | 1 |
| Tan, NS | 1 |
| Loo, SCJ | 1 |
| Montilla-García, Á | 1 |
| Tejada, MÁ | 1 |
| Perazzoli, G | 1 |
| Entrena, JM | 1 |
| Portillo-Salido, E | 1 |
| Fernández-Segura, E | 1 |
| Cañizares, FJ | 1 |
| Cobos, EJ | 1 |
| Aghazadeh-Habashi, A | 1 |
| Asghar, W | 1 |
| Jamali, F | 1 |
| Singh, R | 1 |
| Thota, S | 1 |
| Bansal, R | 1 |
| Yellepeddi, VK | 1 |
| Radhakrishnan, J | 1 |
| Radhakrishnan, R | 1 |
| Dante, MCL | 1 |
| Borgheti-Cardoso, LN | 1 |
| Fantini, MCA | 1 |
| Praça, FSG | 1 |
| Medina, WSG | 1 |
| Pierre, MBR | 1 |
| Lara, MG | 1 |
| Dey, R | 1 |
| Sultana, S | 1 |
| Bishayi, B | 1 |
| Mhillaj, E | 1 |
| Morgese, MG | 1 |
| Tucci, P | 1 |
| Furiano, A | 1 |
| Luongo, L | 1 |
| Bove, M | 1 |
| Maione, S | 1 |
| Cuomo, V | 1 |
| Schiavone, S | 1 |
| Trabace, L | 1 |
| Timur, UT | 1 |
| Caron, MMJ | 1 |
| Bastiaansen-Jenniskens, YM | 1 |
| Welting, TJM | 1 |
| van Rhijn, LW | 1 |
| van Osch, GJVM | 1 |
| Emans, PJ | 2 |
| Mazhari, S | 1 |
| Razi, M | 1 |
| Sadrkhanlou, R | 1 |
| Grimm, H | 1 |
| Kretzschmar, J | 1 |
| Cook, MD | 1 |
| Brown, MD | 1 |
| Pouran, B | 1 |
| de Visser, HM | 1 |
| Weinans, HH | 1 |
| Thomas, RE | 1 |
| Kik, MJL | 1 |
| Grinwis, GCM | 1 |
| Thies, JC | 1 |
| Woike, N | 1 |
| Wang, YP | 1 |
| Wang, QY | 1 |
| Li, CH | 1 |
| Li, XW | 1 |
| Xu, X | 3 |
| Sang, W | 1 |
| Zhu, L | 1 |
| Lu, H | 1 |
| Ma, J | 1 |
| Kwon, JY | 1 |
| Lee, SH | 2 |
| Na, HS | 1 |
| Jung, K | 1 |
| Choi, J | 1 |
| Cho, KH | 1 |
| Lee, CY | 1 |
| Kim, SJ | 1 |
| Park, SH | 1 |
| Shin, DY | 1 |
| Cho, ML | 1 |
| Huang, X | 1 |
| Zhong, L | 1 |
| van Helvoort, E | 1 |
| Lafeber, F | 1 |
| Mastbergen, S | 1 |
| Hendriks, J | 1 |
| Post, JN | 1 |
| Karperien, M | 1 |
| Antunes, DM | 1 |
| Rodrigues, MFSD | 1 |
| Guimarães, DM | 1 |
| Duarte, CME | 1 |
| Miguita, L | 1 |
| Corrêa, L | 1 |
| DE Oliveira, APL | 1 |
| Fernandes, KPS | 1 |
| Nunes, FD | 1 |
| Valvassori, SS | 1 |
| Dal-Pont, GC | 1 |
| Tonin, PT | 1 |
| Varela, RB | 1 |
| Ferreira, CL | 1 |
| Gava, FF | 1 |
| Andersen, ML | 1 |
| Soares, JC | 1 |
| Quevedo, J | 1 |
| Abdellatif, KRA | 1 |
| Abdelall, EKA | 1 |
| Labib, MB | 1 |
| Fadaly, WAA | 1 |
| Zidan, TH | 1 |
| Tageldin, GN | 1 |
| Ibrahim, TM | 1 |
| Fahmy, SM | 1 |
| Ashour, HM | 1 |
| Khalil, MA | 1 |
| Nassra, RA | 1 |
| Labouta, IM | 1 |
| Essex, MN | 1 |
| Zhang, RY | 1 |
| Berger, MF | 1 |
| Upadhyay, S | 1 |
| Park, PW | 1 |
| Kaizaki, A | 1 |
| Tien, LT | 1 |
| Pang, Y | 1 |
| Cai, Z | 1 |
| Tanaka, S | 1 |
| Numazawa, S | 1 |
| Bhatt, AJ | 1 |
| Fan, LW | 1 |
| Kumar, V | 1 |
| Kaur, K | 2 |
| Gupta, GK | 1 |
| Gupta, AK | 1 |
| Yaseen, S | 1 |
| Ovais, S | 1 |
| Bashir, R | 1 |
| Rathore, P | 1 |
| Samim, M | 1 |
| Nair, V | 1 |
| Javed, K | 1 |
| Wang, LJ | 1 |
| Bai, L | 1 |
| Su, D | 1 |
| Zhang, T | 1 |
| Mao, ZY | 1 |
| Kraus, S | 2 |
| Hummler, S | 1 |
| Toriola, AT | 1 |
| Poole, EM | 1 |
| Scherer, D | 1 |
| Kotzmann, J | 1 |
| Makar, KW | 1 |
| Kazanov, D | 2 |
| Galazan, L | 1 |
| Naumov, I | 2 |
| Coghill, AE | 1 |
| Duggan, D | 1 |
| Gigic, B | 1 |
| Arber, N | 2 |
| Ulrich, CM | 1 |
| Paulissen, SM | 1 |
| van Hamburg, JP | 1 |
| Davelaar, N | 1 |
| Asmawidjaja, PS | 1 |
| Hazes, JM | 1 |
| Lubberts, E | 1 |
| Tomić, MA | 2 |
| Micov, AM | 2 |
| Stepanović-Petrović, RM | 2 |
| Kovacevic, JM | 1 |
| Boškovic, BD | 1 |
| Maciel, IS | 1 |
| Silva, RB | 1 |
| Morrone, FB | 1 |
| Calixto, JB | 2 |
| Campos, MM | 1 |
| Setia, S | 1 |
| Nehru, B | 1 |
| Sanyal, SN | 1 |
| Di Penta, A | 1 |
| Chiba, A | 1 |
| Alloza, I | 1 |
| Wyssenbach, A | 1 |
| Yamamura, T | 1 |
| Villoslada, P | 1 |
| Miyake, S | 1 |
| Vandenbroeck, K | 1 |
| Kim, YG | 1 |
| Udayanga, KG | 1 |
| Totsuka, N | 1 |
| Weinberg, JB | 1 |
| Núñez, G | 1 |
| Shibuya, A | 1 |
| Kargar, M | 1 |
| Yousefi, A | 1 |
| Mojtahedzadeh, M | 1 |
| Akhondzadeh, S | 2 |
| Artounian, V | 1 |
| Abdollahi, A | 1 |
| Ahmadvand, A | 1 |
| Ghaeli, P | 1 |
| Brookshire, HL | 1 |
| English, RV | 1 |
| Nadelstein, B | 1 |
| Weigt, AK | 1 |
| Gift, BW | 1 |
| Gilger, BC | 1 |
| El-Sayed, RM | 1 |
| Moustafa, YM | 1 |
| El-Azab, MF | 1 |
| de Melo, TR | 1 |
| Chelucci, RC | 1 |
| Pires, ME | 1 |
| Barbieri, KP | 1 |
| Bosquesi, PL | 1 |
| Trossini, GH | 1 |
| Chung, MC | 1 |
| dos Santos, JL | 1 |
| Darwish, HA | 1 |
| Arab, HH | 1 |
| Abdelsalam, RM | 1 |
| Annamanedi, M | 1 |
| Kalle, AM | 1 |
| Kim, JY | 1 |
| Alam, F | 1 |
| Chung, SW | 1 |
| Park, J | 1 |
| Jeon, OC | 1 |
| Kim, SY | 1 |
| Son, WC | 1 |
| Byun, Y | 1 |
| Vera, M | 1 |
| Barcia, E | 1 |
| Negro, S | 1 |
| Marcianes, P | 1 |
| García-García, L | 1 |
| Slowing, K | 1 |
| Fernández-Carballido, A | 1 |
| Rabinow, B | 1 |
| Werling, J | 1 |
| Bendele, A | 1 |
| Gass, J | 1 |
| Bogseth, R | 1 |
| Balla, K | 1 |
| Valaitis, P | 1 |
| Hutchcraft, A | 1 |
| Graham, S | 1 |
| Fink, SP | 1 |
| Dawson, DM | 1 |
| Kresak, A | 1 |
| Lawrence, EG | 1 |
| Yang, P | 1 |
| Barnholtz-Sloan, JS | 1 |
| Willis, JE | 1 |
| Kopelovich, L | 1 |
| Markowitz, SD | 1 |
| Li, S | 1 |
| Jiang, M | 2 |
| Bi, Y | 2 |
| Xu, J | 2 |
| Han, M | 2 |
| Zhang, PX | 1 |
| Cheng, J | 1 |
| Zou, S | 1 |
| D'Souza, AD | 1 |
| Koff, JL | 1 |
| Lu, J | 1 |
| Lee, PJ | 1 |
| Krause, DS | 1 |
| Egan, ME | 1 |
| Bruscia, EM | 1 |
| Abdelgawad, MA | 1 |
| Elshemy, HA | 1 |
| Alsayed, SS | 1 |
| Kamel, G | 1 |
| Gan, ZM | 1 |
| Wang, XD | 1 |
| Lv, DH | 1 |
| Liu, D | 1 |
| Li, L | 1 |
| Patel, SK | 1 |
| Beaino, W | 1 |
| Anderson, CJ | 1 |
| Beaudin, AE | 1 |
| Waltz, X | 1 |
| Pun, M | 1 |
| Wynne-Edwards, KE | 1 |
| Ahmed, SB | 1 |
| Anderson, TJ | 1 |
| Hanly, PJ | 1 |
| Poulin, MJ | 1 |
| Qureshi, RA | 1 |
| Tian, Y | 1 |
| McDonald, MK | 1 |
| Capasso, KE | 1 |
| Douglas, SR | 1 |
| Gao, R | 1 |
| Orlova, IA | 1 |
| Barrett, JE | 1 |
| Ajit, SK | 1 |
| Sacan, A | 1 |
| Arabzadeh, S | 1 |
| Ameli, N | 1 |
| Zeinoddini, A | 1 |
| Rezaei, F | 1 |
| Farokhnia, M | 1 |
| Mohammadinejad, P | 1 |
| Ghaleiha, A | 1 |
| Lee, S | 1 |
| Lee, Y | 1 |
| Kim, W | 1 |
| Nam, J | 1 |
| Jeong, S | 1 |
| Yoo, JW | 1 |
| Kim, MS | 1 |
| Moon, HR | 1 |
| Jung, Y | 1 |
| Zheng, H | 1 |
| Guo, Q | 1 |
| He, S | 1 |
| Hirasaki, Y | 1 |
| Hou, W | 1 |
| Hua, B | 1 |
| Li, C | 1 |
| Bao, Y | 1 |
| Gao, Y | 1 |
| Qi, X | 1 |
| Pei, Y | 1 |
| Laux-Biehlmann, A | 1 |
| Boyken, J | 1 |
| Dahllöf, H | 1 |
| Schmidt, N | 1 |
| Zollner, TM | 1 |
| Nagel, J | 1 |
| Gould, SA | 1 |
| Doods, H | 1 |
| Lamla, T | 1 |
| Pekcec, A | 1 |
| Negi, AK | 1 |
| Bhatnagar, A | 1 |
| Agnihotri, N | 1 |
| Kondreddy, VK | 1 |
| Kamatham, AN | 1 |
| Bazan, L | 1 |
| Bendas, ER | 1 |
| El Gazayerly, ON | 1 |
| Badawy, SS | 1 |
| Xiao, Y | 1 |
| Yin, Z | 1 |
| Shahbazi, S | 1 |
| Sahrawat, TR | 1 |
| Ray, M | 1 |
| Dash, S | 1 |
| Kar, D | 1 |
| Kumar, G | 1 |
| Goldberg, SN | 1 |
| Wang, Y | 2 |
| Velez, E | 1 |
| Gourevitch, S | 1 |
| Galun, E | 1 |
| Ahmed, M | 1 |
| Lu, CH | 1 |
| Hung, YJ | 1 |
| Hsieh, PS | 2 |
| Ilhan, N | 1 |
| Gungor, H | 1 |
| Gul, HF | 1 |
| Eroksuz, H | 1 |
| Villa, V | 1 |
| Thellung, S | 1 |
| Bajetto, A | 1 |
| Gatta, E | 1 |
| Robello, M | 1 |
| Novelli, F | 1 |
| Tasso, B | 1 |
| Tonelli, M | 1 |
| Florio, T | 1 |
| Voloshyna, I | 1 |
| Kasselman, LJ | 1 |
| Carsons, SE | 1 |
| Littlefield, MJ | 1 |
| Gomolin, IH | 1 |
| De Leon, J | 1 |
| Reiss, AB | 1 |
| Ozer, EK | 1 |
| Goktas, MT | 1 |
| Kilinc, I | 1 |
| Bariskaner, H | 1 |
| Ugurluoglu, C | 1 |
| Iskit, AB | 1 |
| González-Gay, MA | 1 |
| González-Juanatey, C | 1 |
| Peck, Y | 1 |
| Leom, LT | 1 |
| Low, PFP | 1 |
| Wang, DA | 1 |
| Hiller, JG | 1 |
| Sampurno, S | 1 |
| Millen, R | 1 |
| Kuruvilla, N | 1 |
| Ho, KM | 1 |
| Ramsay, R | 1 |
| Riedel, B | 1 |
| Kido, LA | 1 |
| Montico, F | 1 |
| Vendramini-Costa, DB | 1 |
| Pilli, RA | 1 |
| Cagnon, VHA | 1 |
| Rezaei, M | 1 |
| Rasekh, HR | 1 |
| Ahmadiani, A | 1 |
| Pourahmad, J | 1 |
| Noguchi, M | 1 |
| Kimoto, A | 1 |
| Sasamata, M | 1 |
| Miyata, K | 1 |
| Narayanan, NK | 1 |
| Nargi, D | 1 |
| Horton, L | 1 |
| Reddy, BS | 1 |
| Bosland, MC | 1 |
| Narayanan, BA | 1 |
| Moghaddam, HF | 1 |
| Hemmati, A | 1 |
| Nazari, Z | 1 |
| Mehrab, H | 1 |
| Abid, KM | 1 |
| Ardestani, MS | 1 |
| Mello, GC | 1 |
| Desouza, IA | 1 |
| Mariano, NS | 1 |
| Ferreira, T | 1 |
| Macedo, ML | 1 |
| Antunes, E | 1 |
| Aroeira, LS | 1 |
| Lara-Pezzi, E | 1 |
| Loureiro, J | 1 |
| Aguilera, A | 1 |
| Ramírez-Huesca, M | 1 |
| González-Mateo, G | 1 |
| Pérez-Lozano, ML | 1 |
| Albar-Vizcaíno, P | 1 |
| Bajo, MA | 1 |
| del Peso, G | 1 |
| Sánchez-Tomero, JA | 1 |
| Jiménez-Heffernan, JA | 1 |
| Selgas, R | 1 |
| López-Cabrera, M | 1 |
| Rezende, RM | 4 |
| Dos Reis, WG | 4 |
| Duarte, ID | 1 |
| Lima, PP | 1 |
| Bakhle, YS | 5 |
| de Francischi, JN | 4 |
| Futaki, N | 1 |
| Harada, M | 1 |
| Sugimoto, M | 1 |
| Hashimoto, Y | 1 |
| Honma, Y | 1 |
| Arai, I | 1 |
| Nakaike, S | 1 |
| Hoshi, K | 1 |
| Goldstein, BI | 1 |
| Kemp, DE | 1 |
| Soczynska, JK | 1 |
| McIntyre, RS | 1 |
| Parada, B | 1 |
| Sereno, J | 1 |
| Reis, F | 1 |
| Teixeira-Lemos, E | 1 |
| Garrido, P | 1 |
| Pinto, AF | 1 |
| Cunha, MF | 1 |
| Pinto, R | 1 |
| Mota, A | 1 |
| Figueiredo, A | 1 |
| Teixeira, F | 1 |
| Haagen, J | 1 |
| Krohn, H | 1 |
| Röllig, S | 1 |
| Schmidt, M | 1 |
| Wolfram, K | 1 |
| Dörr, W | 1 |
| Gao, M | 1 |
| Wang, M | 1 |
| Miller, KD | 1 |
| Hutchins, GD | 1 |
| Zheng, QH | 1 |
| Boyce-Rustay, JM | 1 |
| Zhong, C | 1 |
| Kohnken, R | 1 |
| Baker, SJ | 1 |
| Simler, GH | 1 |
| Wensink, EJ | 1 |
| Decker, MW | 1 |
| Honore, P | 1 |
| Flórez, A | 1 |
| de Haro, J | 1 |
| Martínez, E | 1 |
| Varela, C | 1 |
| Bleda, S | 1 |
| Acín, F | 1 |
| Khayyal, MT | 2 |
| El-Ghazaly, MA | 2 |
| Nada, AS | 1 |
| Ueno, T | 1 |
| Suzuki, T | 1 |
| Oikawa, A | 1 |
| Hosono, K | 1 |
| Kosaka, Y | 1 |
| Amano, H | 1 |
| Kitasato, H | 1 |
| Toda, M | 1 |
| Hayashi, I | 1 |
| Kato, T | 1 |
| Ito, Y | 1 |
| Sugimoto, Y | 1 |
| Narumiya, S | 1 |
| Okamoto, H | 1 |
| Majima, M | 1 |
| Lu, KC | 1 |
| Chiang, CF | 1 |
| Queiroz-Junior, CM | 1 |
| Pacheco, CM | 1 |
| Fonseca, AH | 1 |
| Klein, A | 1 |
| Caliari, MV | 1 |
| Yoon, DS | 1 |
| Yoo, JH | 1 |
| Paik, S | 1 |
| Han, CD | 1 |
| Lee, JW | 1 |
| Mateos, JL | 1 |
| Coon, KD | 1 |
| Inge, LJ | 1 |
| Swetel, K | 1 |
| Felton, V | 1 |
| Stafford, P | 1 |
| Bremner, RM | 1 |
| Hotz-Behofsits, C | 1 |
| Simpson, RJ | 1 |
| Walley, M | 1 |
| Bjarnason, IT | 1 |
| Roh, GS | 1 |
| Yi, CO | 1 |
| Cho, YJ | 1 |
| Jeon, BT | 1 |
| Nizamudtinova, IT | 1 |
| Kim, HJ | 1 |
| Kim, JH | 1 |
| Oh, YM | 1 |
| Huh, JW | 1 |
| Lee, JH | 1 |
| Hwang, YS | 1 |
| Lee, SD | 1 |
| Lee, JD | 1 |
| Gassani, BC | 1 |
| Paiva-Lima, P | 3 |
| Ferreira-Alves, DL | 2 |
| Cunha, NV | 1 |
| de Abreu, SB | 1 |
| Panis, C | 1 |
| Grassiolli, S | 1 |
| Guarnier, FA | 1 |
| Cecchini, R | 1 |
| Mazzuco, TL | 1 |
| Pinge-Filho, P | 1 |
| Martins-Pinge, MC | 1 |
| Camêlo, VM | 2 |
| Jiang, B | 1 |
| Zeng, Y | 1 |
| Li, MJ | 1 |
| Xu, JY | 1 |
| Zhang, YN | 1 |
| Wang, QJ | 1 |
| Sun, NY | 1 |
| Lu, T | 1 |
| Wu, XM | 1 |
| Mohy El-Din, MM | 1 |
| Senbel, AM | 1 |
| Bistawroos, AA | 1 |
| El-Mallah, A | 1 |
| Nour El-Din, NA | 1 |
| Bekhit, AA | 1 |
| Abd El Razik, HA | 1 |
| Li, DQ | 1 |
| Zhong, J | 1 |
| Wu, XL | 1 |
| Peng, H | 1 |
| Liu, SQ | 1 |
| Kalonia, H | 1 |
| Kumar, A | 1 |
| Gravitz, L | 1 |
| Sagiv, E | 1 |
| Sheffer, M | 1 |
| Shapira, S | 1 |
| Domany, E | 1 |
| Zhao, H | 1 |
| Feng, Y | 1 |
| Yang, B | 1 |
| Xing, Z | 1 |
| Chan, AT | 1 |
| Sima, CS | 1 |
| Zauber, AG | 1 |
| Ridker, PM | 1 |
| Hawk, ET | 1 |
| Bertagnolli, MM | 2 |
| Shatzel, J | 1 |
| Wooten, K | 1 |
| Ankola, A | 1 |
| Cheney, RT | 1 |
| Morrison, CD | 1 |
| Skitzki, JJ | 1 |
| Roy, LD | 1 |
| Pathangey, LB | 1 |
| Tinder, TL | 1 |
| Gruber, HE | 1 |
| Mukherjee, P | 1 |
| Uddin, MJ | 1 |
| Crews, BC | 1 |
| Ghebreselasie, K | 1 |
| Huda, I | 1 |
| Kingsley, PJ | 1 |
| Ansari, MS | 1 |
| Tantawy, MN | 1 |
| Reese, J | 1 |
| Marnett, LJ | 1 |
| Mukherjee, D | 1 |
| Coates, PJ | 1 |
| Lorimore, SA | 1 |
| Wright, EG | 1 |
| Macciò, A | 1 |
| Madeddu, C | 1 |
| Gramignano, G | 1 |
| Mulas, C | 1 |
| Floris, C | 1 |
| Sanna, E | 1 |
| Cau, MC | 1 |
| Panzone, F | 1 |
| Mantovani, G | 1 |
| Gong, L | 1 |
| Thorn, CF | 1 |
| Grosser, T | 1 |
| Altman, RB | 1 |
| Klein, TE | 1 |
| Faraco, A | 1 |
| Francischi, JN | 2 |
| Robinson, I | 1 |
| Sargent, B | 1 |
| Hatcher, JP | 1 |
| Liu, Q | 1 |
| Jia, J | 1 |
| Zoccal, KF | 1 |
| Bitencourt, Cda S | 1 |
| Sorgi, CA | 1 |
| Bordon, Kde C | 1 |
| Sampaio, SV | 1 |
| Arantes, EC | 1 |
| Faccioli, LH | 1 |
| Konger, RL | 1 |
| Xu, Z | 1 |
| Sahu, RP | 1 |
| Rashid, BM | 1 |
| Mehta, SR | 1 |
| Mohamed, DR | 1 |
| DaSilva-Arnold, SC | 1 |
| Bradish, JR | 1 |
| Warren, SJ | 1 |
| Kim, YL | 1 |
| Chuang, HC | 1 |
| Hsueh, TW | 1 |
| Chang, CC | 1 |
| Hwang, JS | 1 |
| Chuang, KJ | 1 |
| Yan, YH | 1 |
| Cheng, TJ | 1 |
| Paulsen, G | 1 |
| Egner, I | 1 |
| Raastad, T | 1 |
| Reinholt, F | 1 |
| Owe, S | 1 |
| Lauritzen, F | 1 |
| Brorson, SH | 1 |
| Koskinen, S | 1 |
| de Rienzo-Madero, B | 1 |
| Coffeen, U | 1 |
| Simón-Arceo, K | 1 |
| Mercado, F | 1 |
| Jaimes, O | 1 |
| Magis-Weinberg, L | 1 |
| Contreras, B | 1 |
| Pellicer, F | 1 |
| García-Rodríguez, RM | 1 |
| Hinojosa, M | 1 |
| Camacho-Garrido, E | 1 |
| Berges Gimeno, P | 1 |
| Martín García, C | 1 |
| Kisley, LR | 1 |
| Barrett, BS | 1 |
| Dwyer-Nield, LD | 1 |
| Bauer, AK | 1 |
| Thompson, DC | 1 |
| Malkinson, AM | 1 |
| Chaves, CT | 1 |
| Moura, AC | 1 |
| Lima, AS | 1 |
| Rocha, OA | 1 |
| Pinheiro, RM | 1 |
| Abdel-Salam, OM | 2 |
| Baiuomy, AR | 2 |
| El-Shenawy, SM | 1 |
| Arbid, MS | 2 |
| Siqueira-Junior, JM | 1 |
| Peters, RR | 1 |
| Brum-Fernandes, AJ | 1 |
| Ribeiro-do-Valle, RM | 1 |
| Patrignani, P | 1 |
| Hsueh, SF | 1 |
| Lu, CY | 1 |
| Chao, CS | 1 |
| Tan, PH | 1 |
| Huang, YW | 1 |
| Hsieh, SW | 1 |
| Hsiao, HT | 1 |
| Chung, NC | 1 |
| Lin, SH | 1 |
| Huang, PL | 1 |
| Lyu, PC | 1 |
| Yang, LC | 1 |
| Jayr, C | 1 |
| Chu, AJ | 1 |
| Chou, TH | 1 |
| Chen, BD | 1 |
| Chu, K | 1 |
| Jeong, SW | 1 |
| Jung, KH | 1 |
| Han, SY | 1 |
| Lee, ST | 1 |
| Kim, M | 1 |
| Roh, JK | 1 |
| Lu, YM | 1 |
| Dong, XY | 1 |
| Mets, T | 1 |
| Bautmans, I | 1 |
| Njemini, R | 1 |
| Lambert, M | 1 |
| Demanet, C | 1 |
| Subramanian, N | 1 |
| Ghosal, SK | 1 |
| Moulik, SP | 1 |
| Alhan, E | 1 |
| Kalyoncu, NI | 1 |
| Ercin, C | 1 |
| Kural, BV | 1 |
| Yin, LL | 1 |
| Zhang, WY | 1 |
| Li, MH | 1 |
| Shen, JK | 1 |
| Zhu, XZ | 1 |
| Ferrario, A | 1 |
| Fisher, AM | 1 |
| Rucker, N | 1 |
| Gomer, CJ | 1 |
| Whitehouse, MW | 1 |
| Abdallah, DM | 1 |
| Okpanyi, SN | 1 |
| Kelber, O | 1 |
| Weiser, D | 1 |
| Nishiyama, T | 1 |
| Müller, N | 1 |
| Schwarz, MJ | 1 |
| Dehning, S | 1 |
| Douhe, A | 1 |
| Cerovecki, A | 1 |
| Goldstein-Müller, B | 1 |
| Spellmann, I | 1 |
| Hetzel, G | 1 |
| Maino, K | 1 |
| Kleindienst, N | 1 |
| Möller, HJ | 1 |
| Arolt, V | 1 |
| Riedel, M | 1 |
| Taddei, S | 1 |
| Caraccio, N | 1 |
| Virdis, A | 1 |
| Dardano, A | 1 |
| Versari, D | 1 |
| Ghiadoni, L | 1 |
| Ferrannini, E | 1 |
| Salvetti, A | 1 |
| Monzani, F | 1 |
| Matson, DJ | 1 |
| Broom, DC | 1 |
| Carson, SR | 1 |
| Baldassari, J | 1 |
| Kehne, J | 1 |
| Cortright, DN | 1 |
| Rathi, BS | 1 |
| Wagh, NK | 1 |
| Bodhankar, SL | 1 |
| Kulkarni, VM | 1 |
| Hilário, MO | 1 |
| Terreri, MT | 1 |
| Len, CA | 1 |
| Hunter, RL | 1 |
| Dragicevic, N | 1 |
| Seifert, K | 1 |
| Choi, DY | 1 |
| Liu, M | 1 |
| Kim, HC | 1 |
| Cass, WA | 1 |
| Sullivan, PG | 1 |
| Bing, G | 1 |
| Park, EK | 1 |
| Rhee, HI | 1 |
| Jung, HS | 1 |
| Ju, SM | 1 |
| Lee, YA | 1 |
| Hong, SJ | 1 |
| Yang, HI | 1 |
| Yoo, MC | 1 |
| Kim, KS | 1 |
| Myint, AM | 1 |
| Steinbusch, HW | 1 |
| Goeghegan, L | 1 |
| Luchtman, D | 1 |
| Kim, YK | 1 |
| Leonard, BE | 1 |
| Okumura, T | 1 |
| Sakakibara, A | 1 |
| Murata, Y | 1 |
| Kita, Y | 1 |
| Queiroz, AF | 1 |
| Moura, RM | 1 |
| Ribeiro, JK | 1 |
| Lyra, IL | 1 |
| Cunha, DC | 1 |
| Santos, EA | 1 |
| de-Sales, MP | 1 |
| Jain, S | 1 |
| Sapra, B | 1 |
| Tiwary, AK | 1 |
| Ziegler, J | 1 |
| Smith, CJ | 1 |
| Koboldt, CM | 1 |
| Muhammad, J | 1 |
| Zweifel, BS | 1 |
| Shaffer, A | 1 |
| Talley, JJ | 1 |
| Masferrer, JL | 1 |
| Seibert, K | 1 |
| Isakson, PC | 1 |
| Hamilton, LC | 1 |
| Mitchell, JA | 1 |
| Tomlinson, AM | 1 |
| Warner, TD | 1 |
| Tindall, E | 1 |
| Muscará, MN | 1 |
| McKnight, W | 1 |
| Asfaha, S | 1 |
| Wallace, JL | 1 |
| McAdam, BF | 1 |
| Mardini, IA | 1 |
| Habib, A | 1 |
| Burke, A | 1 |
| Lawson, JA | 1 |
| Kapoor, S | 1 |
| FitzGerald, GA | 1 |
| Niederberger, E | 1 |
| Tegeder, I | 1 |
| Vetter, G | 1 |
| Schmidtko, A | 1 |
| Schmidt, H | 1 |
| Euchenhofer, C | 1 |
| Bräutigam, L | 1 |
| Grösch, S | 1 |
| Geisslinger, G | 1 |
| Ferencik, M | 1 |
| Novak, M | 1 |
| Rovensky, J | 1 |
| Rybar, I | 1 |
| Mejza, F | 1 |
| Nizankowska, E | 1 |
| Kessenich, CR | 1 |
| Granados-Soto, V | 2 |
| Alonso-López, R | 2 |
| Asomoza-Espinosa, R | 2 |
| Rufino, MO | 1 |
| Gomes-Lopes, LD | 1 |
| Ferreira, SH | 1 |
| Torres-López, JE | 1 |
| Ortiz, MI | 1 |
| Castañeda-Hernández, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-center, Open Label, Random Clinical Trial of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis[NCT01934933] | Phase 4 | 150 participants (Actual) | Interventional | 2014-09-24 | Completed | ||
| Precision Psychiatry: Anti-inflammatory Medication in Immuno-metabolic Depression[NCT05415397] | Phase 3 | 140 participants (Anticipated) | Interventional | 2022-09-28 | Recruiting | ||
| The Safety and Effectiveness of Probiotic Supplementation on Bipolar Depression: a Proof of Concept Randomized Controlled Trial[NCT02155972] | Phase 2 | 16 participants (Actual) | Interventional | 2013-05-31 | Terminated (stopped due to The trial was terminated because of inability to recruit the needed number of participants) | ||
| Effect of Celecoxib on Postoperative Narcotic Use and Disease Severity in Patients With Aspirin-exacerbated Respiratory Disease and Chronic Rhinosinusitis: a Randomised Controlled Trial[NCT04147013] | Phase 4 | 44 participants (Anticipated) | Interventional | 2020-02-18 | Recruiting | ||
| Prevention of Sporadic Colorectal Adenomas With Celecoxib[NCT00005094] | Phase 3 | 1,170 participants (Anticipated) | Interventional | 2000-03-31 | Completed | ||
| A Randomized Control Trial Study of the Efficacy of Celecoxib Versus Ketorolac for Perioperative Pain Control[NCT03331315] | Phase 2 | 170 participants (Actual) | Interventional | 2013-09-01 | Completed | ||
| Single Dose Oral Celecoxib (With or Without Acetaminophen) for Acute Post-operative Pain Following Impacted Third Molar Surgery.[NCT04790812] | Phase 4 | 100 participants (Anticipated) | Interventional | 2021-04-22 | Recruiting | ||
| Multi-center, Prospective Randomized, Comparative Open With Blinded Endpoints (PROBE) Trial to Assess the Safety and Effectiveness of Administration of Celecoxib in Patients With Intracerebral Hemorrhage[NCT00526214] | 44 participants (Actual) | Interventional | 2007-10-31 | Completed | |||
| The Effect of a Sea-safety Course on Mood, Mental Wellbeing and Inflammation[NCT04528485] | 61 participants (Actual) | Interventional | 2020-07-01 | Completed | |||
| Minocycline as an Adjunct for the Treatment of Depressive Symptoms: Pilot Randomized Controlled Trial[NCT02263872] | Phase 4 | 41 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Salicylic Augmentation in Depression[NCT03152409] | Phase 2 | 74 participants (Anticipated) | Interventional | 2018-11-15 | Recruiting | ||
| Cytokine Responses to Acute Inflammation in the Oral Surgery Model[NCT00006175] | 160 participants | Observational | 2000-08-31 | Completed | |||
| The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin[NCT03869268] | Phase 4 | 72 participants (Actual) | Interventional | 2019-04-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Average inpatient hydromorphone use measured in milligrams (NCT03331315)
Timeframe: 48 hrs following surgery
| Intervention | Milligrams (Mean) |
|---|---|
| Ketorolac | 0.7 |
| Celecoxib | 0.8 |
Average inpatient ondansetron use measured in milligrams (NCT03331315)
Timeframe: 48 hrs following surgery
| Intervention | Milligrams (Mean) |
|---|---|
| Ketorolac | 1.5 |
| Celecoxib | 1.3 |
Pain measured using the Visual Analog Scale, no pain (0-0.4 cm), mild pain(0.5-4.4 cm), moderate pain (4.5-7.4 cm), and severe pain (7.5-10.0 cm). Subscale scoring was not used in analysis but provided as reference for patient and nursing staff. (NCT03331315)
Timeframe: 48 hrs following surgery
| Intervention | units on a scale (Mean) |
|---|---|
| Ketorolac | 2.7 |
| Celecoxib | 2.4 |
Measured using postoperative questionnaire (NCT03331315)
Timeframe: 2 weeks after discharge
| Intervention | Days (Mean) |
|---|---|
| Ketorolac | 5.7 |
| Celecoxib | 3.8 |
Number of oral narcotic pills used after discharge until 2 week postoperative visit. (NCT03331315)
Timeframe: 2 weeks after discharge
| Intervention | Pills (Mean) |
|---|---|
| Ketorolac | 8.1 |
| Celecoxib | 6.0 |
Perioperative Complications measured intraoperatively and postoperatively by type (NCT03331315)
Timeframe: During and after surgery
| Intervention | Patients (Number) |
|---|---|
| Ketorolac | 5 |
| Celecoxib | 6 |
Average number of days required for complete return to independent activities of daily living (NCT03331315)
Timeframe: 2 weeks after discharge
| Intervention | Days (Mean) |
|---|---|
| Ketorolac | 2.4 |
| Celecoxib | 2.2 |
Total hospital stay from time fo admission to time of discharge measured in hours (NCT03331315)
Timeframe: Following surgery
| Intervention | Hours (Mean) |
|---|---|
| Ketorolac | 11.6 |
| Celecoxib | 11.9 |
18 reviews available for celecoxib and Innate Inflammatory Response
| Article | Year |
|---|---|
Benzimidazole: an emerging scaffold for analgesic and anti-inflammatory agents.
Topics: Analgesics; Anti-Inflammatory Agents; Benzimidazoles; Drug Discovery; Humans; Inflammation; Pain | 2014 |
Anti-inflammatory activity of triazine derivatives: A systematic review.
Topics: Animals; Anti-Inflammatory Agents; Humans; Inflammation; Structure-Activity Relationship; Triazines | 2019 |
Human disorders associated with inflammation and the evolving role of natural products to overcome.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biological Products; Cardiovascular | 2019 |
Contemporary advances of cyclic molecules proposed for inflammation.
Topics: Animals; Anti-Inflammatory Agents; Dose-Response Relationship, Drug; Humans; Inflammation; Molecular | 2021 |
Metabolomic Studies for Metabolic Alterations Induced by Non-Steroidal Anti-Inflammatory Drugs: Mini Review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Humans; Ibuprofen; Inflammation; Metabo | 2021 |
A journey of celecoxib from pain to cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Humans; Inflam | 2020 |
Progress in PET Imaging of Neuroinflammation Targeting COX-2 Enzyme.
Topics: Animals; Anti-Inflammatory Agents; Blood-Brain Barrier; Brain; Celecoxib; Central Nervous System Dis | 2021 |
Safety of celecoxib compared with placebo and non-selective NSAIDs: cumulative meta-analysis of 89 randomized controlled trials.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topi | 2013 |
Developments in synthesis of the anti-inflammatory drug, celecoxib: a review.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Celecoxib; Cy | 2013 |
Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature.
Topics: Anti-Inflammatory Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Brief Psychiatric | 2009 |
[Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review].
Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Administration Routes; Evidence-Based Medicine | 2010 |
[Analgesic effects of cyclooxygenase 2 inhibitors].
Topics: Acute Disease; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Cycl | 2004 |
Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications.
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Carcinogens | 2004 |
Nonsteroidal anti-inflammatory drugs: cyclooxygenase 2 inhibitors.
Topics: Adolescent; Aspirin; Celecoxib; Child; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Interacti | 2006 |
Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox | 1999 |
Alzheimer's disease, inflammation and non-steroidal anti-inflammatory drugs.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Celecoxib; Cyclooxygenas | 2001 |
[Selective cyclooxygenase 2 inhibitors (COX-2)].
Topics: Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitor | 2001 |
Cyclo-oxygenase 2 inhibitors: an important new drug classification.
Topics: Acute Disease; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Celecoxib; Chr | 2001 |
23 trials available for celecoxib and Innate Inflammatory Response
| Article | Year |
|---|---|
Effect of celecoxib combined with glucosamine hydrochloride in promoting the functional recovery and decreasing the inflammatory factor levels in patients with knee osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Sedimentation; C-Reactive Protein; Celecoxib; Female; | 2021 |
Etanercept/celecoxib on improving MRI inflammation of active ankylosing spondylitis: A multicenter, open-label, randomized clinical trial.
Topics: Adult; Celecoxib; Etanercept; Humans; Inflammation; Magnetic Resonance Imaging; Spondylitis, Ankylos | 2022 |
Sustained release of locally delivered celecoxib provides pain relief for osteoarthritis: a proof of concept in dog patients.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Delayed-Ac | 2023 |
Sustained release of locally delivered celecoxib provides pain relief for osteoarthritis: a proof of concept in dog patients.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Delayed-Ac | 2023 |
Sustained release of locally delivered celecoxib provides pain relief for osteoarthritis: a proof of concept in dog patients.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Delayed-Ac | 2023 |
Sustained release of locally delivered celecoxib provides pain relief for osteoarthritis: a proof of concept in dog patients.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Delayed-Ac | 2023 |
Lipopolysaccharide-induced immune stress negatively regulates broiler chicken growth
Topics: Animals; Celecoxib; Chickens; Cyclooxygenase 2; Cytokines; Dinoprostone; Inflammation; Lipopolysacch | 2023 |
No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial.
Topics: Antidepressive Agents; Australia; C-Reactive Protein; Celecoxib; Depression; Depressive Disorder, Ma | 2021 |
The Efficacy of Imrecoxib and Celecoxib in Axial Spondyloarthritis and Their Influence on Serum Dickopff-Related Protein 1 (DKK-1) Levels.
Topics: Biomarkers; Celecoxib; Demography; Follow-Up Studies; Humans; Inflammation; Intercellular Signaling | 2017 |
Effect of Celecoxib on Surgical Site Inflammation after Total Knee Arthroplasty: A Randomized Controlled Study.
Topics: Aged; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement, Knee; | 2018 |
Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT).
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents; Celecoxib; Cognit | 2013 |
Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Col | 2013 |
Effects of celecoxib on inflammatory markers in bipolar patients undergoing electroconvulsive therapy: a placebo-controlled, double-blind, randomised study.
Topics: Adult; Biomarkers; Bipolar Disorder; C-Reactive Protein; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyt | 2014 |
[Perioperative immunomodulatory therapy does not decrease postoperative recurrence rate of rectal cancer].
Topics: C-Reactive Protein; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Immunomodulation; Inflammation; | 2015 |
Human intermittent hypoxia-induced respiratory plasticity is not caused by inflammation.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cross-Over Studies; Double-Blind Method; | 2015 |
Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Bipolar Disorder; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drug Therapy, | 2015 |
Impact of celecoxib on inflammation during cancer surgery: a randomized clinical trial.
Topics: Aged; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Follow-Up Studies; Humans; Inflammation; Male; | 2017 |
Selective cyclooxygenase-2 inhibition reduces endothelial dysfunction and improves inflammatory status in patients with intermittent claudication.
Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelium, Vascular; Female; Humans; Inflammation; Intermi | 2009 |
Comparison of different loading dose of celecoxib on postoperative anti-inflammation and analgesia in patients undergoing endoscopic nasal surgery-200 mg is equivalent to 400 mg.
Topics: Adult; Celecoxib; Cyclooxygenase 2 Inhibitors; Endoscopy; Female; Humans; Inflammation; Male; Middle | 2011 |
C-reactive protein and risk of colorectal adenoma according to celecoxib treatment.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; C-Reactive Protein; Cardiovascular | 2011 |
A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life.
Topics: Adult; Aged; Antioxidants; Cachexia; Carnitine; Celecoxib; Female; Genital Neoplasms, Female; Humans | 2012 |
Inflammatory markers CD11b, CD16, CD66b, CD68, myeloperoxidase and neutrophil elastase in eccentric exercised human skeletal muscles.
Topics: Adult; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Biomarkers; CD11b Antigen; Celecoxib | 2013 |
The influence of celecoxib on muscle fatigue resistance and mobility in elderly patients with inflammation.
Topics: Acute Disease; Aged; Aged, 80 and over; C-Reactive Protein; Celecoxib; Cyclooxygenase Inhibitors; Cy | 2004 |
The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Anti-Anxiety Agents; Antidepressive Agents; Celecoxib; Cyclooxy | 2006 |
The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Anti-Anxiety Agents; Antidepressive Agents; Celecoxib; Cyclooxy | 2006 |
The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Anti-Anxiety Agents; Antidepressive Agents; Celecoxib; Cyclooxy | 2006 |
The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Anti-Anxiety Agents; Antidepressive Agents; Celecoxib; Cyclooxy | 2006 |
The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Anti-Anxiety Agents; Antidepressive Agents; Celecoxib; Cyclooxy | 2006 |
The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Anti-Anxiety Agents; Antidepressive Agents; Celecoxib; Cyclooxy | 2006 |
The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Anti-Anxiety Agents; Antidepressive Agents; Celecoxib; Cyclooxy | 2006 |
The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Anti-Anxiety Agents; Antidepressive Agents; Celecoxib; Cyclooxy | 2006 |
The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Anti-Anxiety Agents; Antidepressive Agents; Celecoxib; Cyclooxy | 2006 |
Low-grade systemic inflammation causes endothelial dysfunction in patients with Hashimoto's thyroiditis.
Topics: Acetylcholine; Adult; Algorithms; Ascorbic Acid; Celecoxib; Cyclooxygenase 2; Endothelium, Vascular; | 2006 |
Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation.
Topics: Adult; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxy | 2000 |
200 other studies available for celecoxib and Innate Inflammatory Response
| Article | Year |
|---|---|
Naphthalene derivatives: A new series of selective cyclooxygenase-2 inhibitors.
Topics: Animals; Anti-Inflammatory Agents; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inh | 2001 |
Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Binding Sites | 2003 |
Synthesis and structure-activity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 (COX-2) selective inhibitors.
Topics: Acute Disease; Administration, Oral; Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cycloox | 2003 |
3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selective inhibitor: synthesis and biological evaluation.
Topics: Administration, Oral; Animals; Carrageenan; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxyg | 2005 |
2-Amino-5-thiazolyl motif: a novel scaffold for designing anti-inflammatory agents of diverse structures.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Chronic Disease; Cyclooxygenase Inhib | 2008 |
Synthesis and biological evaluation of 2-trifluoromethyl/sulfonamido-5,6-diaryl substituted imidazo[2,1-b]-1,3,4-thiadiazoles: a novel class of cyclooxygenase-2 inhibitors.
Topics: Animals; Anti-Inflammatory Agents; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Edema; In | 2008 |
Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 1-(4-methanesulfonylphenyl)-5-aryl-1H-pyrazol-3-carboxylic acids: synthesis, nitric oxide release studies and anti-inflammatory activities.
Topics: Animals; Anti-Inflammatory Agents; Cyclooxygenase 2 Inhibitors; Esters; Hydrazines; Inflammation; Mo | 2008 |
Synthesis of new 4-[2-(4-methyl(amino)sulfonylphenyl)-5-trifluoromethyl-2H-pyrazol-3-yl]-1,2,3,6-tetrahydropyridines: a search for novel nitric oxide donor anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Carrageenan; Celecoxib; Edema; Inflammation; Nitric Oxid | 2008 |
Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase.
Topics: Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Cyclooxygenase 1; Cyclooxygenase 2; Drug | 2008 |
Synthesis of 1-(methanesulfonyl- and aminosulfonylphenyl)acetylenes that possess a 2-(N-difluoromethyl-1,2-dihydropyridin-2-one) pharmacophore: evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.
Topics: Acetylene; Alkynes; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; Cyc | 2009 |
Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.
Topics: Amines; Animals; Brain; Chemistry, Pharmaceutical; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Di | 2009 |
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Potent and orally efficacious benzothiazole amides as TRPV1 antagonists.
Topics: Amides; Animals; Benzothiazoles; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; I | 2012 |
Synthesis of novel 2-mercaptobenzoxazole based 1,2,3-triazoles as inhibitors of proinflammatory cytokines and suppressors of COX-2 gene expression.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoxazoles; Cyclooxygenase 2; Cycloo | 2014 |
Synthesis of new 1-(4-methane(amino)sulfonylphenyl)-5-(4-substituted-aminomethylphenyl)-3-trifluoromethyl-1H-pyrazoles: a search for novel nitric oxide donor anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents; Carrageenan; Celecoxib; Edema; Inflammation; Nitric Oxide; Nitric | 2014 |
Benzo[d]imidazole Transient Receptor Potential Vanilloid 1 Antagonists for the Treatment of Pain: Discovery of trans-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Mavatrep).
Topics: Analgesics; Animals; Benzimidazoles; Biological Availability; Carrageenan; Dogs; Freund's Adjuvant; | 2015 |
Anti-allergic inflammatory components from Sanguisorba officinalis L.
Topics: Animals; Anti-Allergic Agents; beta-N-Acetylhexosaminidases; Dose-Response Relationship, Drug; Enzym | 2018 |
Tailoring the Substitution Pattern on 1,3,5-Triazine for Targeting Cyclooxygenase-2: Discovery and Structure-Activity Relationship of Triazine-4-Aminophenylmorpholin-3-one Hybrids that Reverse Algesia and Inflammation in Swiss Albino Mice.
Topics: Analgesics; Animals; Carrageenan; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Design; Drug D | 2018 |
Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase.
Topics: Acetylcholine; Alzheimer Disease; Animals; Cell Line; Cholinesterase Inhibitors; Cyclooxygenase 2 In | 2019 |
Modification of the lead molecule: Tryptophan and piperidine appended triazines reversing inflammation and hyeperalgesia in rats.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 In | 2020 |
Synthesis, biological evaluation of benzothiazole derivatives bearing a 1,3,4-oxadiazole moiety as potential anti-oxidant and anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents; Benzothiazoles; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Fr | 2020 |
Design and synthesis of 7-O-1,2,3-triazole hesperetin derivatives to relieve inflammation of acute liver injury in mice.
Topics: Animals; Carbon Tetrachloride; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Dru | 2021 |
Investigations on substituted (2-aminothiazol-5-yl)(imidazo[1,2-a]pyridin-3-yl)methanones for the treatment of Alzheimer's disease.
Topics: Aluminum Chloride; Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dose-Respons | 2021 |
Preparation, optimization and evaluation of transdermal therapeutic system of celecoxib to treat inflammation for treatment of rheumatoid arthritis.
Topics: Administration, Cutaneous; Arthritis, Rheumatoid; Celecoxib; Emulsions; Humans; Inflammation; Skin A | 2021 |
PACER lncRNA regulates COX-2 expression in lung cancer cells.
Topics: Arachidonic Acid; Celecoxib; Cyclooxygenase 2; Cytokines; Dinoprostone; Humans; Inflammation; Lung; | 2022 |
Long-term anti-inflammatory effects of injectable celecoxib nanoparticle hydrogels for Achilles tendon regeneration.
Topics: Achilles Tendon; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cytok | 2022 |
Development of stealth liposomal formulation of celecoxib: In vitro and in vivo evaluation.
Topics: Celecoxib; Cholesterol; Humans; Inflammation; Liposomes; Polyethylene Glycols; Spectroscopy, Fourier | 2022 |
Dexamethasone microspheres and celecoxib microcrystals loaded into injectable gels for enhanced knee osteoarthritis therapy.
Topics: Animals; Celecoxib; Dexamethasone; Gels; Inflammation; Injections, Intra-Articular; Microspheres; Os | 2022 |
Celecoxib alleviates denervation-induced muscle atrophy by suppressing inflammation and oxidative stress and improving microcirculation.
Topics: Celecoxib; Humans; Inflammation; Microcirculation; Muscle Denervation; Muscle, Skeletal; Muscular At | 2022 |
Selenocoxib-3, a novel anti-inflammatory therapeutic effectively resolves colitis.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colitis; Coli | 2023 |
EXPERIMENTAL RESEARCH OF THE EFFECT OF COXIBS ON THE CERULOPLASMIN LEVEL IN RAT SERUM ON THE FORMALIN-INDUCED EDEMA MODEL.
Topics: Animals; Anti-Inflammatory Agents; Benzenesulfonamides; Celecoxib; Ceruloplasmin; Cyclooxygenase 2 I | 2022 |
Celecoxib activates autophagy by inhibiting the mTOR signaling pathway and prevents apoptosis in nucleus pulposus cells.
Topics: Apoptosis; Autophagy; Celecoxib; Humans; Inflammation; Intervertebral Disc Degeneration; Nucleus Pul | 2022 |
Celecoxib activates autophagy by inhibiting the mTOR signaling pathway and prevents apoptosis in nucleus pulposus cells.
Topics: Apoptosis; Autophagy; Celecoxib; Humans; Inflammation; Intervertebral Disc Degeneration; Nucleus Pul | 2022 |
Celecoxib activates autophagy by inhibiting the mTOR signaling pathway and prevents apoptosis in nucleus pulposus cells.
Topics: Apoptosis; Autophagy; Celecoxib; Humans; Inflammation; Intervertebral Disc Degeneration; Nucleus Pul | 2022 |
Celecoxib activates autophagy by inhibiting the mTOR signaling pathway and prevents apoptosis in nucleus pulposus cells.
Topics: Apoptosis; Autophagy; Celecoxib; Humans; Inflammation; Intervertebral Disc Degeneration; Nucleus Pul | 2022 |
Cyclooxygenase-2 activates EGFR-ERK1/2 pathway via PGE2-mediated ADAM-17 signaling in testosterone-induced benign prostatic hyperplasia.
Topics: ADAM17 Protein; Animals; Celecoxib; Cyclooxygenase 2; Dinoprostone; ErbB Receptors; Hyperplasia; Inf | 2023 |
Liposomal celecoxib combined with dendritic cell therapy enhances antitumor efficacy in melanoma.
Topics: Cancer Vaccines; CD8-Positive T-Lymphocytes; Celecoxib; Dendritic Cells; Humans; Inflammation; Lipos | 2023 |
Imrecoxib and celecoxib affect sacroiliac joint inflammation in axSpA by regulating bone metabolism and angiogenesis.
Topics: Axial Spondyloarthritis; beta Catenin; Celecoxib; Core Binding Factor Alpha 1 Subunit; Humans; Infla | 2023 |
Comparative structural study of selective and non-selective NSAIDs against the enzyme cyclooxygenase-2 through real-time molecular dynamics linked to post-dynamics MM-GBSA and e-pharmacophores mapping.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2; Humans; Inflammation; | 2023 |
Celecoxib attenuates neuroinflammation, reactive astrogliosis and promotes neuroprotection in young rats with experimental hydrocephalus.
Topics: Animals; Celecoxib; Cyclooxygenase 2; Gliosis; Humans; Hydrocephalus; Inflammation; Male; Neuroinfla | 2023 |
Exploring COX-2 inhibitors in tuberculosis: A whole-blood model approach for immune response and adjunt therapy evaluation.
Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Humans; Immunity; Inflammati | 2023 |
COX-2 inhibition rescues depression-like behaviors via suppressing glial activation, oxidative stress and neuronal apoptosis in rats.
Topics: Animals; Antidepressive Agents; Apoptosis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 2019 |
Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Celecoxib; Ce | 2019 |
Design, Synthesis and Investigation of the Potential Anti-Inflammatory Activity of 7-
Topics: Animals; Celecoxib; Cyclooxygenase 2; Gene Expression Regulation; Hesperidin; Humans; Hydrophobic an | 2019 |
Role of anti-inflammatory interventions in high-fat-diet-induced obesity.
Topics: Animals; Anti-Inflammatory Agents; Celecoxib; Cytokines; Diet, High-Fat; Disease Models, Animal; Fat | 2020 |
Combatting joint pain and inflammation by dual inhibition of monoacylglycerol lipase and cyclooxygenase-2 in a rat model of osteoarthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthralgia; Benzodioxoles; Celecoxib; Cyclooxygenase 2 Inhibitors | 2020 |
Antinociceptive and anti-inflammatory effects of 4-(arylchalcogenyl)-1H-pyrazoles containing selenium or sulfur.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Celecoxib; Disease Models, Animal; Dose-Response Rela | 2020 |
Sex Differences Revealed in a Mouse CFA Inflammation Model with Macrophage Targeted Nanotheranostics.
Topics: Adjuvants, Immunologic; Administration, Intravenous; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxyg | 2020 |
The effect of celecoxib in traumatic heterotopic ossification around temporomandibular joint in mice.
Topics: Animals; Bone Morphogenetic Protein Receptors, Type I; Cartilage, Articular; Celecoxib; Cell Differe | 2020 |
Celecoxib reduces Deoxynivalenol induced proliferation, inflammation and protein kinase C translocation via modulating downstream targets in mouse skin.
Topics: Animals; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Female; Infla | 2020 |
Anti-inflammatory treatment of bipolar depression: promise and disappointment.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Antirheumatic Agents; Biomarkers; Bipolar Disorder; | 2020 |
Anti-inflammatory and analgesic effect of LD-RT and some novel thiadiazole derivatives through COX-2 inhibition.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Celecoxib; Combined Modality Therapy; Cyclooxygenase | 2020 |
Neuroprotective effect of novel celecoxib derivatives against spinal cord injury via attenuation of COX-2, oxidative stress, apoptosisand inflammation.
Topics: Apoptosis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Humans; Inflammation; Molecular | 2020 |
Nano wet milled celecoxib extended release microparticles for local management of chronic inflammation.
Topics: Celecoxib; Drug Liberation; Humans; Inflammation; Lactic Acid; Osteoarthritis; Particle Size | 2020 |
Identification of Potential COX-2 Inhibitors for the Treatment of Inflammatory Diseases Using Molecular Modeling Approaches.
Topics: Animals; Binding Sites; Caco-2 Cells; Celecoxib; Cyclooxygenase 2 Inhibitors; Dogs; Drug Evaluation, | 2020 |
Microglial Activation and Response to Anti-inflammatory Treatment in Major Depressive Disorder: Another Piece in the Inflammation-Mood Disorders Puzzle.
Topics: Anti-Inflammatory Agents; Celecoxib; Depressive Disorder, Major; Humans; Inflammation; Mood Disorder | 2020 |
Therapeutic effects of celecoxib polymeric systems in rat models of inflammation and adjuvant-induced rheumatoid arthritis.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Celecoxib; Freund's Adjuvant; Inflammation; | 2020 |
Influence of Experimental Autoimmune Prostatitis on Sexual Function and the Anti-inflammatory Efficacy of Celecoxib in a Rat Model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Autoimmune Diseases; Celecoxib; Depression; Diseas | 2020 |
Antioxidant and anti-inflammatory effects of piperine on UV-B-irradiated human HaCaT keratinocyte cells.
Topics: Alkaloids; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Benzodioxoles; Celecoxib; Cell Line; D | 2020 |
COX-2 Is Downregulated in Human Stenotic Aortic Valves and Its Inhibition Promotes Dystrophic Calcification.
Topics: Aged; Aged, 80 and over; Animals; Aortic Valve; Aortic Valve Stenosis; Apoptosis; Calcinosis; Celeco | 2020 |
Antinociception produced by nonsteroidal anti-inflammatory drugs in female vs male rats.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Disease Models, Animal; Dos | 2021 |
Celecoxib ameliorates liver cirrhosis via reducing inflammation and oxidative stress along spleen-liver axis in rats.
Topics: Animals; Apoptosis; Celecoxib; China; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Hepatic S | 2021 |
Celecoxib alleviates zinc deficiency-promoted colon tumorigenesis through suppressing inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carcinogenesis; Celecoxib; Colonic Neoplasms; Infl | 2021 |
Fabrication and Evaluation of Celecoxib Oral Oleogel to Reduce the Inflammation of Ulcerative Colitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colitis, Ulcerative; Colon; Dextran Sul | 2021 |
Inhibition of cyclooxygenase-2 enhanced intestinal epithelial homeostasis via suppressing β-catenin signalling pathway in experimental liver fibrosis.
Topics: Animals; beta Catenin; Celecoxib; Cell Line; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease | 2021 |
Montelukast potentiates the antiinflammatory effect of NSAIDs in the rat paw formalin model and simultaneously minimizes the risk of gastric damage.
Topics: Acetates; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclopropan | 2021 |
Physiologically relevant aspirin concentrations trigger immunostimulatory cytokine production by human leukocytes.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecox | 2021 |
Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis.
Topics: Animals; Celecoxib; Cell Movement; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; HEK2 | 2017 |
Controlled-release nanoencapsulating microcapsules to combat inflammatory diseases.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Capsules; Celecoxib; Cimetidine; Delayed-Action Preparation | 2017 |
Grip strength in mice with joint inflammation: A rheumatology function test sensitive to pain and analgesia.
Topics: Acetaminophen; Analgesics; Animals; Arthritis; Celecoxib; Disease Models, Animal; Diterpenes; Female | 2017 |
Drug-Disease Interaction: Effect of Inflammation and Nonsteroidal Anti-Inflammatory Drugs on Cytochrome P450 Metabolites of Arachidonic Acid.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Arthritis, Experimental; Celecox | 2018 |
Studies on 16,17-Pyrazoline Substituted Heterosteroids as Anti-Alzheimer and Anti-Parkinsonian Agents Using LPS Induced Neuroinflammation Models of Mice and Rats.
Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Brain; Celecoxib; Dexamethasone; Drug Evaluation, | 2018 |
Penetration and pharmacokinetics of non-steroidal anti-inflammatory drugs in rat prostate tissue.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Celecoxib; | 2018 |
Liquid Crystalline Systems Based on Glyceryl Monooleate and Penetration Enhancers for Skin Delivery of Celecoxib: Characterization, In Vitro Drug Release, and In Vivo Studies.
Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents; Celecoxib; Chemistry, Pharmaceutical; | 2018 |
Combination treatment of celecoxib and ciprofloxacin attenuates live S. aureus induced oxidative damage and inflammation in murine microglia via regulation of cytokine balance.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Differentia | 2018 |
Celecoxib Prevents Cognitive Impairment and Neuroinflammation in Soluble Amyloid β-treated Rats.
Topics: Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Astrocytes; Brain-Derived N | 2018 |
Celecoxib-mediated reduction of prostanoid release in Hoffa's fat pad from donors with cartilage pathology results in an attenuated inflammatory phenotype.
Topics: Adipose Tissue; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Female; Humans; Inf | 2018 |
Silymarin and celecoxib ameliorate experimental varicocele-induced pathogenesis: evidences for oxidative stress and inflammation inhibition.
Topics: Animals; Antioxidants; Apoptosis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug The | 2018 |
The Effects of Exercise, Aspirin, and Celecoxib in an Atherogenic Environment.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Celecoxib; Cells, Cultured; Epopr | 2018 |
Controlled release of celecoxib inhibits inflammation, bone cysts and osteophyte formation in a preclinical model of osteoarthritis.
Topics: Animals; Anterior Cruciate Ligament; Biocompatible Materials; Bone and Bones; Celecoxib; Cyclooxygen | 2018 |
COX-2 inhibition by celecoxib in epithelial ovarian cancer attenuates E-cadherin suppression through reduced Snail nuclear translocation.
Topics: Blotting, Western; Cadherins; Carcinoma, Ovarian Epithelial; Celecoxib; Cell Line, Tumor; Cyclooxyge | 2018 |
Kartogenin inhibits pain behavior, chondrocyte inflammation, and attenuates osteoarthritis progression in mice through induction of IL-10.
Topics: Anilides; Animals; Cartilage; Cartilage, Articular; Celecoxib; Chondrocytes; Chondrogenesis; Cytokin | 2018 |
The Expressions of Dickkopf-Related Protein 1 and Frizzled-Related Protein Are Negatively Correlated to Local Inflammation and Osteoarthritis Severity.
Topics: Celecoxib; Cross-Sectional Studies; Dinoprostone; Humans; Inflammation; Intracellular Signaling Pept | 2021 |
Nonsteroidal Anti-inflammatory Drugs Modulate Gene Expression of Inflammatory Mediators in Oral Squamous Cell Carcinoma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tu | 2019 |
Coadministration of lithium and celecoxib attenuates the behavioral alterations and inflammatory processes induced by amphetamine in an animal model of mania.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimanic Agents; Behavior, | 2019 |
Design, synthesis of celecoxib-tolmetin drug hybrids as selective and potent COX-2 inhibitors.
Topics: Animals; Anti-Inflammatory Agents; Catalytic Domain; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 I | 2019 |
Synthesis, modeling and biological evaluation of some pyrazolo[3,4-d]pyrimidinones and pyrazolo[4,3-e][1,2,4]triazolo[4,3-a]pyrimidinones as anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents; Binding Sites; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhi | 2019 |
Celecoxib reduces brain dopaminergic neuronaldysfunction, and improves sensorimotor behavioral performance in neonatal rats exposed to systemic lipopolysaccharide.
Topics: Animals; Animals, Newborn; Blotting, Western; Celecoxib; Cyclooxygenase 2 Inhibitors; Dopaminergic N | 2013 |
Synthesis and biological evaluation of 4-arylphthalazones bearing benzenesulfonamide as anti-inflammatory and anti-cancer agents.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Benzenesulfonamides; Celecoxib; Cell Line, | 2013 |
Proinflammatory conditions promote hepatocellular carcinoma onset and progression via activation of Wnt and EGFR signaling pathways.
Topics: Animals; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cell Proliferation; Disease Progres | 2013 |
Synovial fibroblasts directly induce Th17 pathogenicity via the cyclooxygenase/prostaglandin E2 pathway, independent of IL-23.
Topics: Arthritis, Rheumatoid; CD4 Antigens; Celecoxib; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 | 2013 |
Levetiracetam interacts synergistically with nonsteroidal analgesics and caffeine to produce antihyperalgesia in rats.
Topics: Acetaminophen; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caffeine; Celecoxib; Dr | 2013 |
Antihyperalgesic/antinociceptive effects of ceftriaxone and its synergistic interactions with different analgesics in inflammatory pain in rodents.
Topics: Acetaminophen; Analgesics; Analgesics, Non-Narcotic; Animals; Anti-Bacterial Agents; Ceftriaxone; Ce | 2014 |
Synergistic effects of celecoxib and bupropion in a model of chronic inflammation-related depression in mice.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Antidepressive Agents; Behavior, Animal; Brain-Derive | 2013 |
Activation of NF-κB: bridging the gap between inflammation and cancer in colitis-mediated colon carcinogenesis.
Topics: 1,2-Dimethylhydrazine; Animals; Celecoxib; Colitis, Ulcerative; Colonic Neoplasms; Cyclooxygenase 2 | 2014 |
A trifluoromethyl analogue of celecoxib exerts beneficial effects in neuroinflammation.
Topics: Animals; Astrocytes; Axons; Celecoxib; Cells, Cultured; Cyclooxygenase 2 Inhibitors; Cytokines; Dise | 2013 |
Gut dysbiosis promotes M2 macrophage polarization and allergic airway inflammation via fungi-induced PGE₂.
Topics: Adoptive Transfer; Ampicillin; Animals; Anti-Bacterial Agents; Aspirin; Candida; Candidiasis; Cefope | 2014 |
Efficacy of COX-2 inhibitors in controlling inflammation and capsular opacification after phacoemulsification cataract removal.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzophenones; Bromobenzenes; Celecoxib; Cyclooxyg | 2015 |
Evening primrose oil and celecoxib inhibited pathological angiogenesis, inflammation, and oxidative stress in adjuvant-induced arthritis: novel role of angiopoietin-1.
Topics: Administration, Oral; Angiopoietin-1; Animals; Anti-Inflammatory Agents; Antioxidants; Arthritis, Ex | 2014 |
Pharmacological evaluation and preparation of nonsteroidal anti-inflammatory drugs containing an N-acyl hydrazone subunit.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 1; Cyclooxyg | 2014 |
Chrysin alleviates testicular dysfunction in adjuvant arthritic rats via suppression of inflammation and apoptosis: comparison with celecoxib.
Topics: Administration, Oral; Animals; Apoptosis; Arthritis, Experimental; Caspase 3; Celecoxib; Cyclooxygen | 2014 |
Celecoxib sensitizes Staphylococcus aureus to antibiotics in macrophages by modulating SIRT1.
Topics: Animals; Anti-Bacterial Agents; Celecoxib; Humans; Inflammation; Macrophages; Mice; Nitric Oxide; Ox | 2014 |
Combinational chemoprevention effect of celecoxib and an oral antiangiogenic LHD4 on colorectal carcinogenesis in mice.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Azoxymethane; Carci | 2014 |
New celecoxib multiparticulate systems to improve glioblastoma treatment.
Topics: Animals; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2 Inhibito | 2014 |
Intra-articular (IA) ropivacaine microparticle suspensions reduce pain, inflammation, cytokine, and substance p levels significantly more than oral or IA celecoxib in a rat model of arthritis.
Topics: Administration, Oral; Amides; Animals; Arthritis, Experimental; Celecoxib; Cytokines; Inflammation; | 2015 |
Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Azoxymethane; Carc | 2015 |
Lipopolysaccharide induces inflammation and facilitates lung metastasis in a breast cancer model via the prostaglandin E2-EP2 pathway.
Topics: Animals; Blood Vessels; Breast Neoplasms; Celecoxib; Cell Proliferation; Cells, Cultured; Cyclooxyge | 2015 |
Pharmacological modulation of the AKT/microRNA-199a-5p/CAV1 pathway ameliorates cystic fibrosis lung hyper-inflammation.
Topics: Animals; Caveolin 1; Celecoxib; Cystic Fibrosis; Humans; Inflammation; Lung; Macrophages; Mice, Inbr | 2015 |
Synthesis and anti-inflammatory evaluation of new 1,3,5-triaryl-4,5-dihydro-1H-pyrazole derivatives possessing an aminosulphonyl pharmacophore.
Topics: Animals; Anti-Inflammatory Agents; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; Inf | 2015 |
Theranostic nanoemulsions for macrophage COX-2 inhibition in a murine inflammation model.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Celecoxib; Cell Line; Cell Movemen | 2015 |
Circulating microRNA Signatures in Rodent Models of Pain.
Topics: Animals; Celecoxib; Circulating MicroRNA; Disease Models, Animal; Freund's Adjuvant; Gene Expression | 2016 |
Evaluation of glycine-bearing celecoxib derivatives as a colon-specific mutual prodrug acting on nuclear factor-κB, an anti-inflammatory target.
Topics: Animals; Anti-Inflammatory Agents; Celecoxib; Cell Line; Colitis; Colon; Drug Delivery Systems; Drug | 2015 |
Anti-tumor enhancement of Fei-Liu-Ping ointment in combination with celecoxib via cyclooxygenase-2-mediated lung metastatic inflammatory microenvironment in Lewis lung carcinoma xenograft mouse model.
Topics: Animals; Carcinoma, Lewis Lung; Celecoxib; Cyclooxygenase 2; Drugs, Chinese Herbal; Heterografts; In | 2015 |
Dynamic weight bearing as a non-reflexive method for the measurement of abdominal pain in mice.
Topics: Abdominal Pain; Aniline Compounds; Animals; Behavior, Animal; Celecoxib; Chronic Pain; Cyclooxygenas | 2016 |
Pharmacological characterization of intraplantar Complete Freund's Adjuvant-induced burrowing deficits.
Topics: Amines; Analgesics; Animals; Antibodies; Behavior, Animal; Celecoxib; Cyclohexanecarboxylic Acids; D | 2016 |
Celecoxib and fish oil: a combination strategy for decreased inflammatory mediators in early stages of experimental mammary cancer.
Topics: Animals; Anti-Inflammatory Agents; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokin | 2016 |
Celecoxib, a COX-2 inhibitor, synergistically potentiates the anti-inflammatory activity of docosahexaenoic acid in macrophage cell line.
Topics: Animals; Celecoxib; Cell Line; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Docosahe | 2016 |
Comparative pharmaceutical study on colon targeted micro-particles of celecoxib: in-vitro-in-vivo evaluation.
Topics: Acetic Acid; Acrylic Resins; Animals; Celecoxib; Chemistry, Pharmaceutical; Colon; Colonic Neoplasms | 2016 |
Enhanced Anti-Inflammatory Efficacy Through Targeting to Macrophages: Synthesis and In Vitro Evaluation of Folate-Glycine-Celecoxib.
Topics: Animals; Anti-Inflammatory Agents; Celecoxib; Cell Line; Cyclooxygenase 2 Inhibitors; Folic Acid; Gl | 2017 |
Drug Targets for Cardiovascular-Safe Anti-Inflammatory: In Silico Rational Drug Studies.
Topics: Anti-Inflammatory Agents; Aspirin; Binding Sites; Caffeic Acids; Celecoxib; Coumaric Acids; Cyclooxy | 2016 |
Hepatic radiofrequency ablation: markedly reduced systemic effects by modulating periablational inflammation via cyclooxygenase-2 inhibition.
Topics: Animals; Catheter Ablation; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Disease Mode | 2017 |
Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver.
Topics: Adipocytes; Adipokines; Adipose Tissue; AMP-Activated Protein Kinases; Animals; Blood Pressure; Body | 2016 |
Expression of Endoglin and Vascular Endothelial Growth Factor as Prognostic Markers in Experimental Colorectal Cancer.
Topics: Adenocarcinoma; Animals; Biomarkers, Tumor; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibi | 2016 |
Novel celecoxib analogues inhibit glial production of prostaglandin E2, nitric oxide, and oxygen radicals reverting the neuroinflammatory responses induced by misfolded prion protein fragment 90-231 or lipopolysaccharide.
Topics: Animals; Astrocytes; Celecoxib; Cell Line; Cell Proliferation; Cyclooxygenase 2; Dinoprostone; Infla | 2016 |
COX-2-dependent and independent effects of COX-2 inhibitors and NSAIDs on proatherogenic changes in human monocytes/macrophages.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Biological Transport; Celecoxib; Cell Adhe | 2017 |
Celecoxib administration reduced mortality, mesenteric hypoperfusion, aortic dysfunction and multiple organ injury in septic rats.
Topics: Animals; Aorta; Aortic Diseases; Celecoxib; Cytokines; Disease Models, Animal; Female; Glutathione; | 2017 |
Inflammation: NSAIDs and cardiovascular risk in arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Humans; Ibup | 2017 |
Establishment of an in vitro three-dimensional model for cartilage damage in rheumatoid arthritis.
Topics: Animals; Apoptosis; Arthritis, Rheumatoid; Cartilage, Articular; Celecoxib; Cell Culture Techniques; | 2018 |
Goniothalamin and Celecoxib Effects During Aging: Targeting Pro-Inflammatory Mediators in Chemoprevention of Prostatic Disorders.
Topics: Aging; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Celecoxib; Chemoprevention; Drug Mo | 2017 |
Involvement of subcellular organelles in inflammatory pain-induced oxidative stress and apoptosis in the rat hepatocytes.
Topics: Animals; Apoptosis; Aspirin; Celecoxib; Hepatocytes; Inflammation; Male; Organelles; Oxidative Stres | 2008 |
Micro-CT imaging analysis for the effect of celecoxib, a cyclooxygenase-2 inhibitor, on inflammatory bone destruction in adjuvant arthritis rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Bone Diseases; Celecoxib; | 2008 |
Inflammatory processes of prostate tissue microenvironment drive rat prostate carcinogenesis: preventive effects of celecoxib.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Celecoxib; Cell Division; Inflammation; | 2009 |
Effects of aspirin and celecoxib on rigidity in a rat model of Parkinson's disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxygena | 2007 |
Mechanisms involved in the rat peritoneal leukocyte migration induced by a Kunitz-type inhibitor isolated from Dimorphandra mollis seeds.
Topics: Analysis of Variance; Animals; Benzoquinones; Celecoxib; Cell Movement; Dexamethasone; Fabaceae; Ind | 2009 |
Cyclooxygenase-2 mediates dialysate-induced alterations of the peritoneal membrane.
Topics: Adult; Aged; Aged, 80 and over; Animals; Biological Transport, Active; Celecoxib; Cells, Cultured; C | 2009 |
The analgesic actions of centrally administered celecoxib are mediated by endogenous opioids.
Topics: Analgesics, Opioid; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carragee | 2009 |
The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Cel | 2009 |
Anti-inflammatory, anti-proliferative and antioxidant profiles of selective cyclooxygenase-2 inhibition as chemoprevention for rat bladder carcinogenesis.
Topics: Animals; Anticarcinogenic Agents; Celecoxib; Cell Growth Processes; Cyclooxygenase 2 Inhibitors; Inf | 2009 |
Effect of selective inhibitors of inflammation on oral mucositis: preclinical studies.
Topics: Animals; Antibodies, Monoclonal; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Dos | 2009 |
Synthesis of carbon-11 labeled celecoxib derivatives as new candidate PET radioligands for imaging of inflammation.
Topics: Animals; Carbon Radioisotopes; Celecoxib; Humans; Inflammation; Isotope Labeling; Positron-Emission | 2009 |
Comparison of mechanical allodynia and the affective component of inflammatory pain in rats.
Topics: Analgesics, Non-Narcotic; Animals; Behavior, Animal; Celecoxib; Central Nervous System Agents; Diclo | 2010 |
The effects of celecoxib, a COX-2 selective inhibitor, on acute inflammation induced in irradiated rats.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxyge | 2009 |
Recruited bone marrow cells expressing the EP3 prostaglandin E receptor subtype enhance angiogenesis during chronic inflammation.
Topics: Animals; Bone Marrow Cells; Bone Marrow Transplantation; Celecoxib; Cyclooxygenase 2; Cyclooxygenase | 2010 |
Suppressive effect of COX2 inhibitor on the progression of adipose inflammation in high-fat-induced obese rats.
Topics: Adiposity; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Blood Glucose; Blood Pr | 2010 |
Myeloperoxidase content is a marker of systemic inflammation in a chronic condition: the example given by the periodontal disease in rats.
Topics: Animals; Anti-Inflammatory Agents; Biomarkers; Celecoxib; Inflammation; Leukocyte Count; Male; Morph | 2009 |
The effects of COX-2 inhibitor during osteogenic differentiation of bone marrow-derived human mesenchymal stem cells.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Bone Marrow Cells; Celecoxib; Cell | 2010 |
Genomic characterization of the inflammatory response initiated by surgical intervention and the effect of perioperative cyclooxygenase 2 blockade.
Topics: Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokines; Disease Models, Animal | 2010 |
Role of COX-2 in nonsteroidal anti-inflammatory drug enteropathy in rodents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Dinoprostone; Flurbip | 2010 |
Anti-inflammatory effects of celecoxib in rat lungs with smoke-induced emphysema.
Topics: Animals; Anti-Inflammatory Agents; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Celecoxi | 2010 |
Is the sulphonamide radical in the celecoxib molecule essential for its analgesic activity?
Topics: Acetazolamide; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationsh | 2010 |
Cox-2 inhibition attenuates cardiovascular and inflammatory aspects in monosodium glutamate-induced obese rats.
Topics: Adipose Tissue; Animals; Blood; Blood Pressure; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibi | 2010 |
Celecoxib induces tolerance in a model of peripheral inflammatory pain in rats.
Topics: Analgesics; Analysis of Variance; Animals; Celecoxib; Dinoprostone; Hyperalgesia; Indomethacin; Infl | 2010 |
Design, synthesis, and biological evaluation of 1,5-diaryl-1,2,4-triazole derivatives as selective cyclooxygenase-2 inhibitors.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Cyclooxygenase 2 Inhibitor | 2010 |
A novel COX-2 inhibitor pyrazole derivative proven effective as an anti-inflammatory and analgesic drug.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Benzenesulfonamides; Carrageenan; Celecoxib; Chronic | 2011 |
IL-17RA aptamer-mediated repression of IL-6 inhibits synovium inflammation in a murine model of osteoarthritis.
Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; Enzyme-Linked Immunosorbent A | 2011 |
Suppressing inflammatory cascade by cyclo-oxygenase inhibitors attenuates quinolinic acid induced Huntington's disease-like alterations in rats.
Topics: Animals; Brain; Caspase 3; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; H | 2011 |
Chemoprevention: First line of defence.
Topics: Animals; Aspirin; Celecoxib; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Cyclooxygenase I | 2011 |
Gene expression following exposure to celecoxib in humans: pathways of inflammation and carcinogenesis are activated in tumors but not normal tissues.
Topics: Adenocarcinoma; Celecoxib; Cell Cycle; Cell Transformation, Neoplastic; Colonic Polyps; Colorectal N | 2011 |
Inflammatory myofibroblastic tumor of the mesentery: a clinical dilemma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Inflammatory Agents; Celecoxib; Female; Humans; | 2012 |
Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Bone Neoplasms; Celecoxib; Collagen Type | 2011 |
Fluorinated COX-2 inhibitors as agents in PET imaging of inflammation and cancer.
Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Halogenation; Humans; Indomethacin; Inflamm | 2011 |
The in vivo expression of radiation-induced chromosomal instability has an inflammatory mechanism.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Bone Marrow; Celecoxib; Chromosomal In | 2012 |
Celecoxib pathways: pharmacokinetics and pharmacodynamics.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Biomarkers, Pharmacological; | 2012 |
Celecoxib pathways: pharmacokinetics and pharmacodynamics.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Biomarkers, Pharmacological; | 2012 |
Celecoxib pathways: pharmacokinetics and pharmacodynamics.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Biomarkers, Pharmacological; | 2012 |
Celecoxib pathways: pharmacokinetics and pharmacodynamics.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Biomarkers, Pharmacological; | 2012 |
Endogenous opioid and cannabinoid mechanisms are involved in the analgesic effects of celecoxib in the central nervous system.
Topics: Analgesics; Animals; Carrageenan; Celecoxib; Central Nervous System; Cyclooxygenase 2; Cyclooxygenas | 2012 |
Use of dynamic weight bearing as a novel end-point for the assessment of Freund's Complete Adjuvant induced hypersensitivity in mice.
Topics: Adjuvants, Immunologic; Animals; Celecoxib; Chronic Pain; Cyclooxygenase 2 Inhibitors; Endpoint Dete | 2012 |
Primary tumor regulates the pulmonary microenvironment in melanoma carcinoma model and facilitates lung metastasis.
Topics: Animals; Biomarkers, Tumor; Celecoxib; Cyclooxygenase 2 Inhibitors; Cytokines; Female; Inflammation; | 2013 |
Ts6 and Ts2 from Tityus serrulatus venom induce inflammation by mechanisms dependent on lipid mediators and cytokine production.
Topics: Animals; Arachidonate 5-Lipoxygenase; Celecoxib; Cell Movement; Cyclooxygenase 2 Inhibitors; Cytokin | 2013 |
Spatiotemporal assessments of dermal hyperemia enable accurate prediction of experimental cutaneous carcinogenesis as well as chemopreventive activity.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anti-Inflammatory Agents; Carcinogens; Celecoxib; Cell Tr | 2013 |
Nickel-regulated heart rate variability: the roles of oxidative stress and inflammation.
Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents; Antioxidants; Celecoxib; Heart Rate; Inflammation | 2013 |
Taurine enhances antinociception produced by a COX-2 inhibitor in an inflammatory pain model.
Topics: Analgesics; Animals; Carrageenan; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Synergism; Drug Thera | 2013 |
Celecoxib, safe in NSAID intolerance.
Topics: Administration, Oral; Adult; Aged; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; C | 2002 |
Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents; Bu | 2002 |
Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation.
Topics: Animals; Carrageenan; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhib | 2002 |
Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; | 2002 |
The anti-inflammatory effects of the phosphodiesterase inhibitor pentoxifylline in the rat.
Topics: Animals; Anti-Inflammatory Agents; Carrageenan; Celecoxib; Dexamethasone; Dose-Response Relationship | 2003 |
Effects of valeryl salicylate, a COX-1 inhibitor, on models of acute inflammation in mice.
Topics: Acute Disease; Animals; Arachidonic Acid; Carrageenan; Celecoxib; Croton Oil; Cyclooxygenase 1; Cycl | 2003 |
Studies on the anti-inflammatory effect of fluoxetine in the rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Carrageenan; Celecoxib; Cyc | 2004 |
[Clinical pharmacology of selective inhibitors of cyclooxygenase-2].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygena | 2003 |
Nonsteroidal anti-inflammatory drugs increase expression of inducible COX-2 isoform of cyclooxygenase in spinal cord of rats with adjuvant induced inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhi | 2004 |
Celecoxib induces functional recovery after intracerebral hemorrhage with reduction of brain edema and perihematomal cell death.
Topics: Animals; Brain Edema; Celecoxib; Cerebral Hemorrhage; Collagenases; Cyclooxygenase Inhibitors; Dinop | 2004 |
Effects and mechanism of the selective COX-2 inhibitor, celecoxib, on rat colitis induced by trinitrobenzene sulfonic acid.
Topics: Animals; Celecoxib; Colitis; Cyclooxygenase Inhibitors; Dinoprostone; Disease Models, Animal; Inflam | 2004 |
Enhanced in vitro percutaneous absorption and in vivo anti-inflammatory effect of a selective cyclooxygenase inhibitor using microemulsion.
Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents; Celecoxib; Cyclooxygenase Inhibitors; | 2005 |
Effects of the celecoxib on the acute necrotizing pancreatitis in rats.
Topics: Animals; Celecoxib; Ceruletide; Cyclooxygenase Inhibitors; Disease Models, Animal; Edema; Glycodeoxy | 2004 |
CC 05, a novel anti-inflammatory compound, exerts its effect by inhibition of cyclooxygenase-2 activity.
Topics: Animals; Anti-Inflammatory Agents; Baculoviridae; Benzenesulfonamides; Carrageenan; Celecoxib; Cyclo | 2005 |
Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors.
Topics: Animals; Apoptosis; Celecoxib; Cyclooxygenase Inhibitors; Dihematoporphyrin Ether; Dinoprostone; Dru | 2005 |
Prostanoids as friends, not foes: further evidence from the interference by cycloxygenase-inhibitory drugs when inducing tolerance to experimental arthritigens in rats.
Topics: Administration, Oral; Animals; Arthritis, Experimental; Aspirin; Celecoxib; Cyclooxygenase 2; Cycloo | 2005 |
Mechanisms involved in the anti-inflammatory effect of a standardized willow bark extract.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Aspirin; Celecoxib; Cyclooxygenase 1; Cy | 2005 |
Analgesic effects of intrathecally administered celecoxib, a cyclooxygenase-2 inhibitor, in the tail flick test and the formalin test in rats.
Topics: Analgesia; Analysis of Variance; Animals; Behavior, Animal; Celecoxib; Cyclooxygenase 2 Inhibitors; | 2006 |
Inflammation-induced reduction of spontaneous activity by adjuvant: A novel model to study the effect of analgesics in rats.
Topics: Analgesia; Analgesics; Animals; Carrageenan; Celecoxib; Dexamethasone; Dose-Response Relationship, D | 2007 |
Evaluation of anti-inflammatory and analgesic activity of a new class of biphenyl analogs in animal models of inflammation.
Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biphenyl Compounds; C-Rea | 2006 |
Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system.
Topics: Animals; Celecoxib; Cell Death; Corpus Striatum; Cyclooxygenase 2 Inhibitors; Dopamine; In Vitro Tec | 2007 |
Antiinflammatory effects of a combined herbal preparation (RAH13) of Phellodendron amurense and Coptis chinensis in animal models of inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Coptis; Dexamethasone; Disease Models, | 2007 |
Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression.
Topics: Animals; Behavior, Animal; Brain Chemistry; Celecoxib; Cyclooxygenase Inhibitors; Cytokines; Depress | 2007 |
Mathematical analysis of involvement ratio between central and peripheral COX-2 in rat pain models with two types of COX-2 inhibitors with different distribution, celecoxib and CIAA.
Topics: Animals; Carrageenan; Celecoxib; Chlorobenzoates; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Din | 2008 |
Pro-inflammatory effect in mice of CvL, a lectin from the marine sponge Cliona varians.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemotaxis, Leukocyte; Dexamethasone; D | 2008 |
Niosomal gel for site-specific sustained delivery of anti-arthritic drug: in vitro-in vivo evaluation.
Topics: Acrylic Resins; Administration, Cutaneous; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrage | 2007 |
Cancer and arthritis share underlying processes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Arthritis; Celecoxib; Cell Transfo | 1998 |
Pharmacological analysis of cyclooxygenase-1 in inflammation.
Topics: Animals; Arthritis, Experimental; Blood Platelets; Carrageenan; Celecoxib; Cyclooxygenase 1; Cycloox | 1998 |
Synergy between cyclo-oxygenase-2 induction and arachidonic acid supply in vivo: consequences for nonsteroidal antiinflammatory drug efficacy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Celecoxib; Cyclooxygenase 2; Cyc | 1999 |
Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Collagen; Cyclooxygenase 1 | 2000 |
Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Dinoprostone; Disease | 2001 |
Participation of COX, IL-1 beta and TNF alpha in formalin-induced inflammatory pain.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Blocking; Celecoxib; Cyclooxygenase In | 2001 |
Comparison of the antinociceptive effect of celecoxib, diclofenac and resveratrol in the formalin test.
Topics: Analgesia; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Celecoxib; Cyclooxyge | 2002 |